



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:  
Broyles *et al.*

Serial No.: 10/003,669


Filed: November 1, 2001

For: GENE REGULATION THERAPY  
INVOLVING FERRITIN

Group Art Unit: 1632

Examiner: Janice Li Qian

Atty. Dkt. No.: OMRP:027US/SLH

CERTIFICATE OF MAILING 37 C.F.R. § 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date below:	
May 14, 2004 Date	 Steven L. Highlander

DECLARATION OF DR. JOHN McDONALD UNDER 37 C.F.R. §1.132

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450


I, the undersigned, do declare that:

1. I am a citizen of the United States. I currently hold the position of Associate Professor at Washington University School of Medicine. I have over 12 years of research experience in the fields of medicine and neurology. A copy of my *curriculum vitae* is attached.

2. I am familiar with the work of Dr. Robert Broyles relating to ferritin-H as a repressor of the human  $\beta$ -globin gene in erythroid cells – when present in embryonic cells, it represses  $\beta$ -globin, but when absent in adult cells,  $\beta$ -globin is expressed. Thus, ferritin-H appears to be properly characterized as a hemoglobin switching factor.
3. Moreover, I am well aware of the implications this observation has in the treatment of  $\beta$ -globin-related diseases, such as sickle cell anemia. The relevant target cells for this condition (adult erythroid cells) have been shown to express ferritin receptors and to take up exogenously added ferritin protein, and other human cells (astrocytoma cells) which take up exogenous ferritin-H also transport it to the cell nucleus by an active transport mechanism. Thus, using ferritin-H or ferritin-H peptides as a therapeutic agent for treating sickle cell anemia is a logical extension of Dr. Broyles' work.
4. Regarding the feasibility of this approach, protein drugs have been used in clinical settings for several decades. For example, human insulin has been used to treat diabetics, and C-GSF has been used to treat infectious diseases and help to fight cancer. In addition, many other protein drugs have been approved by FDA in recent years. Thus, given what is known about the uptake and transport of ferritin-H, this protein is a promising candidate for treating indications such as sickle cell disease.

5. I hereby declare that all statements made herein of my knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

05/13/04  
Date

  
John W. McDonald, M.D., Ph.D.

CURRICULUM VITAE

John Wood McDonald III, M.D., Ph.D.

Birth Date: June 6, 1963

Social Security #: 348-66-0788

Business Address: Department of Neurology, Campus Box 8518  
Section of Spinal Cord Injury Neurorehabilitation  
Washington University School of Medicine  
4444 Forest Park Avenue  
St. Louis MO 63108  
Tel (314) 454-7825  
Fax (314) 454-5300  
E-mail: mcdonald@neuro.wustl.edu

Home Address: 4465 W Pine #20  
St. Louis MO 63108  
Tel (314) 534-4292

Academic Positions Held:

2001-present Medical Director,  
Spinal Cord Injury Neurorehabilitative Unit  
Rehabilitation Institute of St. Louis  
St. Louis, MO

2003-present Associate Professor of Neurology, Neurological Surgery and  
Neurobiology  
Washington University School of Medicine  
St. Louis, MO

2000-2003 Assistant Professor of Neurological Surgery  
Washington University School of Medicine  
St. Louis, MO

1998-present Assistant Professor of Neurology,  
Barnes-Jewish Hospital  
Washington University School of Medicine  
St. Louis, MO

1998-present Section Head and Director, Spinal Cord Injury Neurorehabilitative  
Unit Barnes-Jewish Hospital and  
Washington University School of Medicine

St. Louis, MO

1996-1998      Instructor, Department of Neurology  
Washington University School of Medicine  
St. Louis, MO

Education:

1993-1996      Residency, Neurology  
Barnes Hospital  
Washington University School of Medicine  
St. Louis, MO

1992-1993      Internship, Preliminary Medicine  
St. Joseph Mercy Hospital  
Ann Arbor, MI

1985-1992      M.D.  
University of Michigan

1985-1992      Ph.D., Neurosciences  
University of Michigan

1991-1992      Visiting Scientist  
Darryle D. Schoepp, Ph.D.  
Eli Lilly and Co.  
Indianapolis, IN

1989-1990      Fellow, Neurology  
Johns Hopkins University School of Medicine

1985            B.S., Liberal Arts and Science, Neurosciences,  
University of Illinois, Champaign-Urbana

Honors and Awards:

St. Louis Business Journal's 40 under 40 Business Leaders in St. Louis for  
outstanding contributions to their field and to the St. Louis Community, St. Louis  
Business Journal, 2002

Medical Director of the Year, Rehabilitation Institute of St. Louis, HealthSouth, 2002

SCI Research Inspiration Award, Sam Schmidt Foundation, Las Vegas, Nevada, 2001

Reeve Research for Freedom Award, Gateway to a Cure, St. Louis, MO, 2000

Nominated one of Top Ten Physician in St. Louis, St. Louis Magazine, 2000

L.W. Freeman, M.D. Award for significant contributions to regenerative spinal cord research, National SCI Association, 1999

Mentored Clinical Scientist Development Award, National Institute of Health, 1996

Murray Goldstein Award, Neurotrauma Society, 1996

S. Weir Mitchell Award, American Academy of Neurology, 1996

Christopher Reeve Paralysis Foundation Research Consortium on Spinal Cord Injury, Consortium Member, 1995-1999

Fellowship, Medical Scientist Training Program, University of Michigan Medical School, 1985-1991

Magna cum laude in Neuroscience, University of Illinois, 1985

Phi Beta Kappa, University of Illinois, 1985

Golden Key National Honorary, University of Illinois, 1985

Phi Kappa Phi, University of Illinois, 1984

Membership in Professional Societies:

American Paraplegia Society, 2000-

Association of Academic Physiatrists, 2000-

American Spine Injury Association (ASIA), 2000-

National Spinal Cord Injury Association, 1999-

Association of Academic Physiatrists, 1999-

International Neurotrauma Society, 1996-

American Association for the Advancement of Science, 1994-

American Neurological Association, 1993-

American Academy of Neurology, 1993-

American Medical Association, Member, 1986-

Society for Neuroscience, Member, 1986-

Research and Clinical Interests:

Spinal cord injury: development of interventions to reduce injury, promote remyelination and enhance regeneration and recovery of function.

Biology of embryonic stem cells and neural progenitor cells.

Mechanisms of oligodendrocyte death: glutamate excitotoxicity.

Mechanisms regulating myelination.

Ontogeny of excitatory amino acid and related neurotransmitter pathways in the brain and their relationship to neurological disease.

Doctoral Thesis:

Co-Mentors: Drs. Michael V. Johnston, M.D. and Anne B. Young, M.D., Ph.D.

Title: Pharmacology and characterization of N-methyl-D-aspartate neurotoxicity in the developing central nervous system.

Symposiums Organized:

Spinal Cord Injury: From bench to bedside. Neuroanatomy Department Saturday Morning Seminar Series, Washington University School of Medicine, 1999.

Neurobiology: Physiologic and pathologic roles of excitatory amino acids during CNS development. Society for Neuroscience, St. Louis, MO, 1990; Lectures: J.W. Olney, M.P. Mattson, J.W. McDonald, H.T. Cline, M. Bear.

Invited Guest Lectures:

April 29-May 1, 2004 Breakfast seminar "Repairing the injured spinal cord: from stem cell to activity-based mechanisms of recovery" presentation and Dinner seminar "Repairing the CNS: from stem cell to activity-based therapies" American Academy of Neurology Annual Meeting, San Francisco, CA

April 14, 2004 "Classes Without Quizzes presentation of Repairing the damaged cord: from stem cell to activity-based mechanisms of recovery" at The Tower Club, Chicago, IL for **Chicago Washington University Club**, sponsored by Alumni Relations Washington University School of Medicine

April 13, 2004 "Repairing the damaged cord: from stem cell to activity-based mechanisms of recovery" presentation for the **Chicago Eliot Society** at the Standard Club, Chicago, IL for Annual Giving Washington University School of Medicine

March 29-April 1, 2004 "Repairing the damaged CNS: From stem cells to activity based therapies" **Royal College of Paediatrics and Child Health, 8<sup>th</sup> Spring Meeting, University of York, York UK**

March 25-26, 2004 "Repairing the damaged spinal cord: From stem cell to activity based mechanisms of recovery" presented at **The William Greenleaf Eliot Society of Kansas City** at Club 1000, Kansas City, MO for Alumni and Development Program Washington University School of Medicine

March 18-19, 2004 "Role of stem cells and repair of the damaged spinal cord presentation to the **BioTherapeutics Research Group, Robarts Research Institute, London, Ontario, Canada** and "Repairing the damaged cord: from stem cell to activity-based mechanisms of recovery" to **Parkwood Hospital SCI Program, Lawson Health Research Institute, London, Ontario, Canada**

March 4 and 5, 2004: "Repair of the damaged spinal cord: from stem cells to activity-based therapies", "Setting up a clinical research team for comprehensive, life-long treatment approaches to spinal cord injury. **Northwest Neuroscience Symposium for Nurses and Other Allied Health Care Professionals, Eugene, Oregon**

February 10, 2004 Stars Program presentation of "Repair of the damaged spinal cord: from stem cell to activity based therapies" at the **University of Missouri St. Louis.**

January 17, 2004 "Repairing the damaged CNS: From stem cells to activity based therapies" **American Society for Peripheral Nerve, The Westin Mission Hills Resort, Palm Springs, CA**

December 8, 2003 "Activity-based rehabilitation for neurorecovery" **The Howard H. Steel Conference, Walt Disney World, Orlando, FL**

November 20, 2003 "Repairing the damaged CNS: From stem cells to activity based therapies" **University of Michigan Fall Short Course, Ann Arbor, MI**

November 18, 2003 "Spinal cord regeneration and repair and integration with the AutoAmbulator" **HealthSouth Medical Director's Conference, Birmingham, AL**



**November 13, 2003 "Stem Cells as Therapeutic Agents" RUNN Course, Woods Hole, MA**

**October 28, 2003 "Spinal cord injury and rehabilitation" BJH Education Committee, Rehabilitation Staff, Barnes-Jewish Hospital, St. Louis, MO**

**October 18-23, 2003 "Repair of the Damaged Cord; from Stem Cell to Activity-Based Recovery Programs" Congress of Neurological Surgeons Meeting, Denver, Colorado**

**October 10, 2003 "The Pathophysiology of Spinal Cord Injuries & Current Research in Activity Based Strategies for Improved Motor Function" AAPM&R Meeting, Chicago, IL**

**October 2, 2003 "Repairing the damaged cord; from stem cell to activity-based mechanisms of recovery" Oklahoma Medical Research Foundation's Work in Progress Seminar, Oklahoma**

**September 14-16, 2003 "The Role of Embryonic Stem Cells in the Repair of the Damaged CNS" Myelin Project Work Group, Acqui Terme, Italy**

**September 10-11, 2003 "Repairing the damaged cord; from stem cell to activity-based mechanisms of recovery" University of Toronto Program in Neuroscience, Toronto, Canada**

**September 2, 2003 "Remyelination: Rationale for Phase-1 Human Trials Neurotransplantation in Spinal Cord Injury, American Paraplegia Society, Las Vegas, Nevada**

**August 14, 2003 "Repairing the damaged cord; from stem cell to activity-based mechanisms of recovery" USCF Grand Rounds, San Francisco, CA**

**August 9, 2003 "Strategies for Spinal Cord Repair After Spinal Cord Injury" ASNR Workshop, Cleveland, OH**

**July 17, 2003 "Development of a Restorative Treatment & Research Spinal Cord Injury Center; Building a Bench to Bedside Transitional System" NSCIA 2003 Convention "Beyond All Barriers", Chicago, IL**

**July 2, 2003 "FES and neuroregeneration: Future convergence or divergence" IFESS Conference, Noosa, Queensland, Australia**

**June 12, 2003 "Recent Progress & Future Promise of Human Embryonic Stem Cells" NIH Stem Cell Symposium, Bethesda, Maryland**

**June 5, 2003 "Repairing the damaged cord: from stem cell to activity-based mechanisms of recovery" Eliot Society Lecture Series, Atlanta, GA**

**June 4, 2003 "Repairing the damaged cord: from stem cell to activity-based mechanisms of recovery" Eliot Society Lecture Series, Washington, DC**

**May 28, 2003 "Repairing the damaged cord: from stem cell to activity-based mechanisms of recovery". Eliot Society Lecture Series, Seattle, WA**

**May 27, 2003 "Repairing the damaged cord: from stem cell to activity-based mechanisms of recovery". Eliot Society Lecture Series, Denver, CO**

**May 9, 2003 "Repairing the Damaged Cord: From Stem Cell to Activity-based Mechanisms of Recovery" Brookhaven National Laboratory Medical Department, Long Island, NY**

**May 5, 2003 "Repairing the Damaged CNS: From Embryonic Stem Cell transplantation to Mobilizing Endogenous Stem Cells" National Organization of Presbyterians, St. Louis, MO**

**April 24, 2003 "Repairing the Damaged CNS: From Stem Cells to Activity-dependent Processes" Life Sciences Speaker Series, Washington University, St. Louis, MO**

**March 31, 2003 "Very Late Recovery Following Spinal Cord Injury: Extension of Evaluation and Outcomes" 2003 AAN Meeting, Honolulu, Hawaii**

**March 8, 2003 "Repairing the Damaged Cord: From Stem Cell to Activity-based Mechanisms of Recovery" St. Louis, MO**

**February 26, 2003 "The Possibilities of Nervous System Repair" Naples Salon, Naples, Florida**

**February 7, 2003 "Repairing the Damaged Cord: From Stem Cell to Activity-based Mechanisms of Recovery", Millikin University, Decatur, IL**

**February 3, 2003 NIH/NINDS Spinal Cord Injury Therapy Workshop, Bethesda, Maryland**

**January 29, 2003 "Repairing the Damaged Cord: From Stem Cell to Activity-based Mechanisms of Recovery" Albany Medical College's Neuroscience Grand Rounds, Albany, New York**

**December 8, 2002 "Repair of the Damaged CNS" Jewish Hospital College of Nursing and Allied Health, St. Louis, MO**

**December 3, 2002 "Repairing the Damaged Spinal Cord: From Stem Cells to Activity-Based Treatments" 3<sup>rd</sup> Asia Pacific Symposium, Sheraton Perth, Western Australia**

**November 21, 2002 "Advances in Neurological Rehabilitation" Washington University School of Medicine Mini-Med School Presentation, St. Louis, MO**

**November 19, 2002 "Promising Strategies to Repair the Damaged Spinal Cord" STARS Program (Student and Teachers as Research Scientist) UMSL, St. Louis, MO**

**November 14, 2002 "Repairing the Damaged Spinal Cord: from stem cells activity-based treatments" 2002 SCI Educational Conference, Phoenix, Arizona**

**November 8, 2002 "Repairing Damaged CNS (Central Nervous System): role of stem cells and activity" The Myelin Project Work Group, Bal Harbor, Florida**

**November 2, 2002 "Neural Transplantation & Activity-Based Recovery" & "Clinical Trials of Intervention for SCT" Clinical Trials in Medical Rehabilitation Conference-(Kessler Institute), Parsippany, New Jersey**

**October 31, 2002 "Stem Cells as Therapeutic Agents" RUNN Course, Woods Hole, Massachusetts**

**October 26, 2002 "Advances in Neurological Rehabilitation; applicability to ALS patients" ALS Project Hope, St. Louis, MO**

**October 18, 2002 "Repairing the Damaged Spinal Cord: from stem cells to activity based recovery programs" American Academy of Neurological Surgery Annual Meeting, Scottsdale, Arizona**

**September 19, 2002 "Repair of the Damaged CNS: the spinal cord injury example" Internal Medicine Grand Rounds, Washington University School of Medicine, St. Louis, MO**

**September 12, 2002 "CNS Repair: What is Do-able" AACPD, New Orleans, Louisiana**

**September 7, 2002 "Repairing the Damaged Spinal Cord" Hendrick Medical Center Fall Symposium, Abilene, Texas**

**August 7, 2002 "Spinal Cord Injury", Summer Stock Lecture Series, Washington University School of Medicine, St. Louis, MO**

**August 7, 2002 "Spinal Cord Injury Update", Barnes-Jewish Hospital Patient Care Leadership, St. Louis, MO**

**June 15, 2002 "Stem Cell Research", Missouri Pharmacy Association Convention, Lake of the Ozarks, MO**

**June 7, 2002 "Cell Transplantation for Spinal Cord Injury Repair", 17<sup>th</sup> Annual Lehman Symposium, Seattle, WA**

**June 6, 2002 "Repairing the Damaged Cord: From activity-based restoration to stem cell transplantation", Northwest Regional SCI Research Forum, Seattle, WA**

**June 4, 2002 "Advances in Neurological Rehabilitation and the Treatment of Spinal Cord Injury", Washington University School of Medicine's Mini-Med School for the Coalition for Plant and Life Sciences, St. Louis, MO**

**May 26-30, 2002 "Therapeutic Applications of Stem Cells", International Healthcare Trip, Geneva, Switzerland**

**May 21, 2002 "Repairing the Damaged Spinal Cord", Missouri Head Injury Advisory Council Conference, Jefferson City, MO**

**May 16, 2002 "Repairing the Damaged Spinal Cord", Reunion Scientific Program: Medical Update '02, St. Louis, MO**

**April 29, 2002 "What are the limits for self-repair in the injured adult CNS?", Neurology & Neurosurgery Research Seminar, St. Louis, MO**

**April 19, 2002 "Stem Cells and Repair of the Injured CNS", MSP Research Symposium, Urbana, IL**

**April 14, 2002 "Future of Spinal Cord Injury: Therapy based on Neural Repair and Gait Retraining, 2002 AAN Meeting, Denver, CO**

**April 9, 2002 "Repairing the Damaged Spinal Cord; ES Cells and Remyelination" Niagara County Community College, San Born, NY**

**April 6, 2002 "Restoring function after spinal cord injury" John Hopkins Board of Trustee Retreat, Baltimore, MD**

**April 2, 2002 "Spinal Cord Injury In-Service" Spinal Cord Presentation to Healthlink, St. Louis, MO**

**March 18, 2002 "Education In-service" The Rehabilitation Institute of St. Louis, St. Louis, MO**

**March 15, 2002 "Repairing the Damaged Spinal Cord: Early Experience with Embryonic Stem Cell Transplantation" 13<sup>th</sup> Annual Spring Brain Conference, Sedona, AZ**

**March 11, 2002 "Repairing the Damaged Spinal Cord; ES Cell Transplantation", The New York Academy of Medicine, New York, NY**

**February 2, 2002 “Stem Cell Research”, Saturday Scholar Program, Belleville, IL**

**January 14, 2002 “Repairing the Damaged Spinal Cord”, Washington University School of Medicine OT Program, St. Louis, MO**

**January 28, 2002 “Stem Cells and Repair of the Damaged CNS: From Scientific Tools to Applied Therapies”, John Hopkins Hospital “Special Seminar”, Baltimore, MD**

**January 23, 2002 “New Concepts in CNS Injury Repair”, Washington University School of Medicine Neurosurgery Grand Rounds, St. Louis, MO**

**January 14, 2002 “Repairing the Damaged Spinal Cord”, Washington University School of Medicine OT Presentation to Faculty & Students, St. Louis, MO**

**December 17, 2001 “Embryonic Stem Cells..from Scientific Tools to Applied Therapies”, Stanford University, Stanford, CA**

**December 15, 2001 “Stem Cells: From Beginnings to Clinical Trials”, 9<sup>th</sup> International Symposium on Neural Regeneration (ISNR), Pacific Grove, CA**

**December 11, 2001 “Repairing the Damaged Spinal Cord: Embryonic Stem Cell Transplantation”, Washington University School of Medicine Emergency Medicine Grand Rounds**

**December 7, 2001 “Neural Stem Cells in Development and Regeneration”, NIAAA Stem Cell Meeting, Bethesda, MD**

**November 1, 2001 “Spinal Cord Injury Repair: Doable Therapeutics”, Keynote Speaker, 2001 Shepherd Center’s Virginia C. Crawford Annual Research Symposium, Shepherd Center, Atlanta, Georgia.**

**October 26, 2001 “Stem Cells as Therapeutic Agents”, RUNN, Wood Hole, Massachusetts**

**October 18, 2001 “Advances in Neurological Rehabilitation”, Washington University School of Medicine Mini-Med School Presentation, St. Louis, MO**

**October 17, 2001 “Stem Cell Research and How It Applies to Other Diseases”, Grace Episcopal Church, St. Louis, MO**

**October 15, 2001 “Stem Cell Research, What’s happening on the frontier of research”, S. Carolina Workers’ Compensation Educational Conference, Myrtle Beach, South Carolina.**

**October 9, 2001 “Regeneration Strategies for the Patient with Spinal Cord Injury” and “Functional Stimulation & Reactivation of the Locomotor Center” Shriners Hospital for Children, Philadelphia, PA**

**September 29, 2001 “Embryonic Stem Cells”, 12<sup>th</sup> Annual Meeting of “The Myelin Project Work Group”, Paris, France**

**September 27, 2001 “Repairing the Damaged Spinal Cord: Doable Therapeutics”, Johns Hopkins Hospital “Grand Rounds”**

**August 1, 2001 “Spinal Cord Regeneration”, Department of Veterans Affairs Spinal Cord Injury Service Grand Rounds, St. Louis, MO**

**July 13, 2001 “Embryonal Stem Cells Promote Functional Recovery in Spinal Injured Animals”, 2<sup>nd</sup> International Transverse Myelitis Symposium, Baltimore, Maryland**

**July 6, 2001 “Spinal Cord Injury Research”, HHMI Summer Seminar, St. Louis, MO**

**June 17, 2001 “Neural Repair and Functional Restoration Workshop-Bridging the Gap”, IFESS 2001, Cleveland, Ohio**

**June 16, 2001 “ES Grafts in Spinal Cord Injury”, 2001 Kentucky Spinal Cord & Head Injury Research Trust Symposium, Louisville, KY**

**May 20, 2001 “Repairing the Damaged Cord”, ASIA, Long Beach, California.**

**May 6, 2001 “Repairing the Damaged Spinal Cord: What is Doable?, XXIII International Symposium, Montreal, Canada**

**May 7, 2001 “Mechanisms of Spinal Cord Recovery after Injury”, AAN, Philadelphia, PA**

**April 27, 2001 “2001 Michael J. Ellis Distinguished Lecture on Disability Science & Practice” University of Illinois, Champaign, IL**

**April 11, 2001 “Repairing the Damaged Spinal Cord: Doable Therapeutics and Development of a World Class Spinal Cord Injury Center”, Clayton Rotary, St. Louis, MO**

**April 7, 2001 “Spinal Cord Regeneration”, Central Society of PM&R Meeting, St. Louis, MO**

**April 2, 2001 “Embryonic Stem Cells and Repair of the Damaged Spinal Cord” American Association of Anatomy, Orlando, Florida**

**March 30, 2001 “Embryonic Stem Cell Differentiation in Oligodendrocytes” 1<sup>st</sup> International Symposium on Clinical Use of Cellular Products, Regensburg, Germany**

**March 8, 2001 “Repair of the Injured CNS: Promoting Oligodendrocytes Remyelination, Spring Brain Conference, Sedona, Arizona**

**March 4, 2001 “Research in Spinal Cord Injury”, Washington University School of Medicine PM&R Presentation, St. Louis, MO**

**February 9, 2001 “Spinal Cord Trauma”, Trends in Trauma Conference, St. Louis, MO**

**February 5, 2001 “Spinal Cord Injury”, Washington University School of Medicine 2<sup>nd</sup> Year Medical School Course, Diseases of the Nervous System”, St. Louis, MO**

**January 27, 2001 “Repair of the Damaged Spinal Cord”, Nasser Institute, Cairo, Egypt.**

**January 23, 2001 “Advances in Spinal Cord Injury Rehabilitation: Scientific Basis of Activity-Dependent Rehabilitation”, Nasser Institute, Cairo, Egypt.**

**January 12, 2001 “Regeneration in the context of FES”, Shriners Hospital, Philadelphia, PA.**

**November 28, 2000 “Stem Cells and CNS Repair: What is Doable?” Department of Immunology and Oncology, National Center of Biotechnology, Madrid, Spain.**

**November 3, 2000 “Stem Cell Transplantation”, Session V: How can the brain and spinal cord be repaired. 18<sup>th</sup> Annual National Neurotrauma Society Symposium, New Orleans, Louisiana.**

**October 20, 2000 “CNS Repair: Stem cell therapies”, Research Updated in Neurobiology and Neurosurgeons (RUNN) 2000, Woods Hole, Massachusetts.**

**September 23, 2000 “Activity-Dependent Rehabilitation”, SJ Rose Symposium, Program for Physical Therapy, Washington University, St. Louis, Missouri.**

**September 12, 2000 “ES cells and Repair of the Damaged Nervous System”, Ataxia-Telangiectasia Foundation, San Diego, California.**

**August 4, 2000 “Repairing the Damaged Spinal Cord”, 14<sup>th</sup> Annual Combined Clinical Conference on Emergency Care, Lake of the Ozarks, MO.**

**July 28, 2000 “ES cells, Remyelination and Recovery of Function”, Geron Corporation, San Francisco, California.**

**July 19, 2000 “Repairing the Damaged Spinal Cord”, Orthopaedics Grand Rounds, Department of Orthopaedics, Washington University School of Medicine, St. Louis, Missouri.**

**July 13, 2000 “Animal Models of Spinal Cord Injury as Paradigms for Stem Cell Therapy”, Food and Drug Administration, Center for Biologics Evaluation and Research, Biological Response Modifiers Advisory Committee, Gaithersburg, Maryland.**

**July 5, 2000 “AMPA- Receptor Mediated Excitotoxicity Contributes to the Selective Loss of Oligodendrocytes in Central Pontine Myelinolysis”, Anesthesia Grand Rounds, Department of Orthopaedics, Washington University School of Medicine, St. Louis, Missouri.**

**June 28, 2000 “Spinal Cord Injury- What is Doable?”, AACD, Spinal Cord Injury Center, Sao Paulo, Brazil.**

**June 25, 2000 “Developing a World Class Spinal Cord Injury Program”, Assetta, Tatui, Brazil.**

**June 10, 2000 “Embryonic Stem (ES) Cells as a Tool and Strategy to Repair the Damaged Nervous System”, Second Hershey Conference- Cerebral Blood Flow and Metabolism, Hotel Hershey, Hershey, Pennsylvania.**

**April 5, 2000 “Spinal Cord Injury- What is doable?; an ES cell transplantation approach”, Neuroscience Lecture Series, Columbia University, Columbia, Missouri.**

**March 29, 2000 “Mechanisms of Spinal Cord Injury. Methods of Repair- What is Doable?”, Department of Neuroradiology, National Institute of Health, Bethesda, Maryland.**

**March 5-8, 2000 “SCI Think Tank”, Kent Waldrep National Paralysis Foundation (KWNPF), Dallas, Texas.**

**January 14, 2000 “Mechanisms of SCI & methods of repair- What is doable?” Neuroscience Lecture Series, Lexington, Kentucky.**

**December 10, 1999 “Mechanisms of SCI & methods of repair- Where do neuroregeneration and neural prostheses meet?” Neural Prosthesis Seminar, Cleveland FES Center, Case Western Reserve University and MetroHealth Medical Center, Cleveland Ohio.**

**December 7, 1999 “Embryonic stem cell transplantation: A strategy for repairing the injured spinal cord.” Advances in Embryonic Stem Cell and Nuclear Transfer**



**Technologies, Asilomar Conference Grounds, Pacific Grove, California. Sponsored by Geron Corporation.**

**University and Hospital Committee Memberships**

2001 -	PNT Committee (Pharmacy & Therapeutics), Rehabilitation Institute of St. Louis
2001- Present	Neurology Executive Committee, Department of Neurology
2001- Present	Medical Executive Committee, Rehabilitation Institute of St. Louis
1999- 2000	Development Committee, Rehabilitation Institute of St. Louis
1998	Occupational Therapy Doctoral Program Steering and Development Committee
1998- 2000	Executive Rehabilitation Committee
1999- Present	Rehabilitation Policy Review Committee

**Teaching Responsibilities:**

**a. Clinical Fellows:**

Cristina Sadowsky, M.D., Spinal Cord Injury Medicine Fellow, 1998-1999

Ramani Gadi, M.D., Spinal Cord Injury Medicine Fellow, 2000-2001

Tan Fung, M.D., Spinal Cord Injury Medicine Fellow, 2001-2002

**b. Research Fellows:**

Yun Qu, M.D., Research Post-doctoral Fellow, 1996-

Mike Howard, Ph.D., Research Post-doctoral Fellow, 1998-

Dan Kadunce, Ph.D., Research Post-doctoral Fellow, 1998-2000

Su Liu, M.D., Ph.D., Research Post-doctoral Fellow, 1998-

Todd Stewart, M.D., Neurosurgery Resident Research Fellow, 1999-2001

Shovan Chakraborty, M.D., Ph.D., Senior Research Fellow, 1999-2000

James Lu, M.D., Neurosurgery Resident Research Fellow, 1999-

Qun Li, Ph.D., Research Post-doctoral Fellow, 2000-

Daniel Becker, M.D., Ph.D., Research Post-doctoral Fellow, 2001-

Husan Ao, M.D., Research Post-doctoral Fellow, 2001-

Ephron Rosenzweig, Research Post-doctoral Fellow, 2003-

David Lenihan, Research Post-doctoral Fellow, 2003

Li Lin, Research Post-doctoral Fellow, 2003

c. Courses and Lectures:

Medical School, presentation to 2<sup>nd</sup> year students, February 1999, 2000, 2001  
Diseases of the Nervous System  
“Spinal Cord Injury”

Spring Saturday Seminar Series, Dept. of Anatomy and Neurobiology, April-June  
1999

“Spinal Cord Injury: from bench to bedside”  
Organized 11 speaker series on SCI, prevention and repair

Bedside and Didactic Teaching:

Neurology Residents

Physical Medicine and Rehabilitation Residents

Medical Students- “Neurologic Assessment”, 2<sup>nd</sup> year medical students

Editorial Referee Responsibilities:

Brain Research  
Brain Research Reviews  
Experimental Neurology  
Journal of Neuroscience  
Journal of Neurotrauma  
Glia  
Lancet  
Nature Biotechnology  
Nature Medicine  
Pediatric Research  
Proceedings of the National Academy of Sciences



Grant Review Responsibilities:

NIH Cell Transplant Special Review, Santa Fe New Mexico, February 21-22, 2001  
New Jersey Spinal Cord Injury Foundation, Review Panel Member, 2001-present  
Special Emphasis Panel Review, Washington, D.C. (NINDS), March 13, 2001  
New York State Spinal Cord Injury Foundation, Review Panel Member, 2000- present  
National Institutes of Health, NINDS, Special Reviewer, 2000-  
Paralyzed Veterans of America Spinal Cord Research Foundation, Regular reviewer,  
1997- present  
International Spinal Cord Research Foundation, 1999- present

Research Grant and Funding Sources:

Active Research Support

Governmental

1R29 NS37927-03	7/1/98-6/30/03	Principle Investigator
CSR/NIH	\$83,995 Annual Direct	
Mechanism of Oligodendrocyte Death in Spinal Cord Injury		
P01 NS39577-01	12/01/99- 11/30/04	Principle Investigator P3
NIH-NINDS	\$141,088 Annual Direct	
ES Cell Transplantation After Spinal Cord Injury: Project 3- Survival and Differentiation of ESNLCs After Transplantation		
P01 DE07734-15	04/01/00- 03/31/05	Principle Investigator P4
NIH-NIDCR	\$132,682 Annual Direct	
Mechanisms of Damage Induced Trigeminal Reorganization: Project 4- Neurotrophin Control of Thalamocortical Development		
1 RO1 NS 40520-01	09/27/00-09/26/03	Principle Investigator
NIH-NINDS	\$250,000 Annual Direct	
ES Cell Myelination in Injured Spinal Cord		

**b. Non-Governmental**

Sam Schmidt Foundation 01/01/02-01/01/03      Principle Investigator  
\$50,000 Annual Direct  
Human Embryonic Stem Cells: Moving from Bench to Bedside

**Past Research Support (Federal and non-Gov.):**

5 K08 NS01931-04 12/01/96-11/30/2000      Principle Investigator  
NIH-NINDS \$85,000 Annual Direct  
AMPA Receptor Mediated Spinal Cord Oligodendrocyte Death

R01 NS36265 9/15/97-9/14/2000      Co-Investigator  
NINDS/NIH \$ 25,000 annual direct  
Oligodendrocyte death in cerebral ischemia  
The major goals of this project are to examine the role of excitotoxic oligodendrocyte death in cerebral ischemia.

SCI STATeam Program Grant 4/1/99- 3/31/01      Principle Investigator  
Barnes-Jewish Hospital Foundation \$120,000 Annual Direct  
STATeam Clinical Care Pathway Implementation and Benefits

KECK Grant 7/1/99- 6/30/00      Co-Investigator  
Keck Foundation \$ 990,000 Annual Direct  
Transplantation of Embryonic Stem Cells in the Injured Spinal Cord

Group Health Grant 10/1/99- 9/31/99      Principle Investigator  
Group Health Foundation \$ 30,000 Annual Direct  
STATeam Clinical Care Pathway Implementation and Benefits

**Clinical Trials Engaged:**

Porcine Fetal Cell Transplantation      Principle Investigator  
Phase I, Porcine Fetal Spinal Cord Cells Treated with Anti-MHC Class I Antibody for Spinal Cord Repair.  
Diacrin, Inc.

**Clinical Trials Completed:**

Fampridine-SR in SCI: SCI-F201      Principle Investigator  
Phase II, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR in Subjects with Chronic, Incomplete Spinal Cord Injury.  
Acorda Therapeutics, Inc.

Neurotrophin-3 in SCI Principle Investigator  
Phase III, Double-Blind, Placebo-Controlled, Cross-Over Study to Evaluate the Efficacy  
of Subcutaneous Neurotrophin-3 in Subjects with Chronic Spinal Cord Injury.  
Regeneron, Inc.

Advisory Board Memberships:

2003- present Chairman, Spinal Cord Injury Research Program Advisory Board,  
University of Missouri at Columbia, Missouri

2001- present Scientific Advisory Board, New York State SCI Research Board, NY, NY.

2000- Present Research Advisory Board Member, Shriners Hospital, Philadelphia, PA

1999- Present Advisory Board Member, Gateway to a Cure, St. Louis, MO

National / Governmental Committees and Responsibilities:

Auxiliary Awards Committee, American Academy of Neurology, 2001- Present.

Special Governmental Consultant, Food and Drug Administration Advisory Committee  
Consultant, Biological Response Modifiers Advisory Committee Meeting #27, Human  
Stem Cells as Cellular Replacement Therapies for Neurological Disorders, Hilton Hotel,  
Gaithersburg, Maryland, July 13-14, 2000.

## BIBLIOGRAPHY

### Publications in Scientific Journals

1. Greenough WT, McDonald JW, Parnisari RM and Camel JE. Environmental conditions modulate degeneration and new dendrite growth in cerebellum of senescent rats. Brain Res. 380: 136-143, 1986.
2. McDonald JW, Silverstein FS and Johnston MV. MK-801 protects the neo-natal brain from hypoxic-ischemic damage. Eur. J. Pharmacol. 140: 359-361, 1987.
3. McDonald JW, Silverstein FS and Johnston MV. Neurotoxicity of N-methyl-D-aspartate is markedly enhanced in developing rat central nervous system. Brain Res. 459: 200-203, 1988.
4. McDonald JW, Silverstein FS and Johnston MV. Neuroprotective effects of MK-801, TCP, PCP and CPP against N-methyl-D-aspartate induced neurotoxicity in an in vivo perinatal rat model. Brain Res. 490: 33-40, 1989.
5. McDonald JW, Cline HT, Constantine-Paton M, Maragos WF, Johnston MV and Young AB. Quantitative autoradiographic localization of NMDA, quisqualate and PCP receptors in frog tectum. Brain Res. 482: 155-158, 1989.
6. McDonald JW, Silverstein FS, Cardona D, Hudson C, Chen R and Johnston MV. Systemic administration of MK-801 protects against N-methyl-D-aspartate and quisqualate mediated neurotoxicity in perinatal rats. Neurosci. 36: 589-599, 1990.
7. McDonald JW, Penney, Jr. JB, Johnston MV and Young AB. Characterization and regional distribution of strychnine-insensitive [<sup>3</sup>H]glycine binding sites in rat brain by quantitative receptor autoradiography. Neurosci. 35(3): 653-668, 1990.
8. McDonald JW, Uckele J, Silverstein FS and Johnston MV. HA-966 (1-Hydroxy-3-aminopyrrolidone-2) selectively reduces N-methyl-D-aspartate (NMDA)-mediated brain damage. Neurosci. Letts. 104:167-170, 1989.
9. McDonald JW, Roeser NF, Silverstein FS and Johnston MV. Quantitative assessment of neuroprotection against NMDA-mediated brain injury. Exp. Neurol. 106: 289-296, 1989.
10. McDonald JW, Silverstein FS and Johnston MV. MK-801 pretreatment enhances NMDA-mediated brain injury and increases brain NMDA recognition site binding in rats. Neurosci. 38: 103-113, 1990.

11. Uckele JE, **McDonald JW**, Johnston MV and Silverstein FS. Effect of glycine and glycine receptor antagonists on NMDA-induced brain injury. Neurosci. Letts. 107: 279-283, 1989.
12. Silverstein FS, **McDonald JW**, Bomarrito M and Johnston MV. Effects of hypoxia-ischemia and MK-801 treatment on the binding of a phencyclidine analogue in the developing brain. Stroke 21(3): 310-315, 1990.
13. **McDonald JW**, Silverstein FS and Johnston MV. Magnesium reduces N-methyl-D-Aspartate (NMDA)-mediated brain injury in perinatal rats. Neurosci. Letts. 109: 234-238, 1990.
14. **McDonald JW** and Johnston MV. Non-ketotic hyperglycinemia: pathophysiological role of N-methyl-D-aspartate type excitatory amino acid receptors. Annals Neurol. (letter) 27(4): 449-450, 1990.
15. **McDonald JW**, Johnston MV and Young AB. Differential ontogenic expression of three receptors comprising the NMDA receptor/channel complex in the rat hippocampus. Exp. Neurol. 110: 237-247, 1990.
16. **McDonald JW** and Johnston MV. Physiological and pathophysiological roles of excitatory amino acids during central nervous system development. Brain Res. Rev. 15(1): 41-70, 1990.
17. **McDonald JW** and Johnston MV. Pharmacology of N-methyl-D-aspartate induced brain injury in an in vivo perinatal rat model. Synapse 6: 179-188, 1990.
18. **McDonald JW**, Trescher WH and Johnston MV. The selective ionotropic-type quisqualate receptor agonist AMPA is a potent neurotoxin in immature brain. Brain Res. 526: 165-168, 1990.
19. Hu B, **McDonald JW**, Johnston MV and Silverstein FS. Excitotoxic brain injury suppresses striatal high affinity glutamate uptake in perinatal rats. J. Neurochem. 56: 933-937, 1991.
20. **McDonald JW**, Chen C-K, Trescher WH and Johnston MV. Effect of body temperature on the severity of excitotoxic brain injury in perinatal rats. Neurosci. Letts. 126: 83-86, 1991.
21. **McDonald JW**, Garofalo EA, Hood T, Sackellares JC, Gilman S, McKeever PE, Troncoso J and Johnston MV. Altered excitatory and inhibitory amino acid receptor binding in hippocampus of patients with temporal lobe epilepsy. Annals Neurol. 29: 529-541, 1991.



22. Debski EA, Cline HT, **McDonald JW**, Constantine-Paton M. Chronic application of NMDA decreases the NMDA sensitivity of the evoked tectal potential in the frog. J. Neurosci. 11: 2947-2957, 1991.
23. Schoepp DD, Johnson BG, Salhoff CR, **McDonald JW** and Johnston MV. In vitro and in vivo pharmacology of trans- and cis-ACPD: dissociation of metabotropic and ionotropic excitatory amino acid receptor effects. J. Neurochem. 56: 1789-1799, 1991.
24. **McDonald JW**, Trescher WH and Johnston MV. Susceptibility of brain to AMPA and quisqualate excitotoxicity transiently peaks during early postnatal development. Brain Res. 583: 54-70, 1992.
25. Hamosh A, **McDonald JW**, Valle D, Francomano CA, Niedermeyer E and Johnston MV. Experience with dextromethorphan and high dose benzoate therapy in an infant with non-ketotic hyperglycinemia. J. Pediatr. 121: 131-135, 1992.
26. **McDonald JW** and Schoepp DD. The metabotropic excitatory amino acid receptor agonist 1S,3R-ACPD selectively potentiates NMDA induced brain injury. Eur. J. Pharmacol. 215: 353-354, 1992.
27. **McDonald JW** and Johnston MV. Neuroprotective synergism of 2-amino-3-phosphonopropionate (D,L-AP3) and MK-801 against ibotenate induced brain injury. Neurosci. Letts. 145: 213-216, 1992.
28. **McDonald JW** and Schoepp DD. Aminooxyacetic acid produces excitotoxic brain injury in neonatal rats. Brain Res. 624: 239-244, 1993.
29. **McDonald JW**, Fix AS, Tizzano JP and Schoepp DD. Seizures and brain injury in neonatal rats induced by 1S,3R-ACPD, a metabotropic glutamate receptor agonist. J. Neurosci. 13: 4445-4455, 1993.
30. Schoepp DD, Lunn WHW, Salhoff CR and **McDonald JW**. The NMDA receptor agonist DL-(tetrazol-5-yl) glycine is a highly potent excitotoxin. Eur. J. Pharmacol. 270: 67-72, 1994.
31. Cline HT, **McDonald JW** and Constantine-Paton M. Glutamate receptor binding in juvenile and adult *Rana pipiens* CNS. J. Neurobiol. 25: 488-502, 1994.
32. Wright RA, **McDonald JW** and Schoepp DD. Distribution and ontogeny of 1S,3R-ACPD-sensitive and quisqualate-insensitive 3H-glutamate binding sites in the rat brain. J. Neurochem. 63: 938-945, 1994.
33. Trescher WH, **McDonald JW** and Johnston MV. Quinolinate-induced injury is enhanced in developing brain. Dev. Brain Res. 83: 224-232, 1994.

34. **McDonald JW**, Bautista RW and Gutmann DH. Pseudo-cervical cord syndrome: a deceptive flumazenil-reversible manifestation of hepatic encephalopathy. Archives Neurol. (letter) 53: 956, 1996.
35. **McDonald JW**, Goldberg MP, Gwag BJ, Chi S-I and Choi DW. Cyclosporine induces neuronal apoptosis and selective oligodendrocyte death in cortical cultures. Annals Neurol. 40: 750-758, 1996.
36. Choi DW, Goldberg MP and **McDonald JW**. Cyclosporine induces neuronal apoptosis and selective oligodendrocyte death in cortical cultures; Reply to Dr. Windebank. Annals Neurol. 41: 563-564, 1997.
37. **McDonald JW**, Behrens MI, Chung C, Bhattacharyya T and Choi DW. Susceptibility to apoptosis is enhanced in immature cortical neurons. Brain Res. 759: 228-232, 1997.
38. Liu XZ, Xu XM, Hu R, Du C, Zhang SX, **McDonald JW**, Dong HX, Wu YJ, Fan GS, Jacquin MF, Hsu CY and Choi DW. Neuronal and glial apoptosis after traumatic spinal cord injury. J. Neurosci. 17: 5395-5406, 1997.
39. **McDonald JW**, Shapiro SM, Silverstein FS and Johnston MV. Role of glutamate mediated excitotoxicity in bilirubin-induced brain injury in the Gunn rat model. Exp. Neurol. 150: 21-29, 1998.
40. **McDonald JW**, Althomsons SP, Hyrc KL, Choi DW and Goldberg MP. Oligodendrocytes are highly vulnerable to AMPA/kainate receptor-mediated excitotoxicity. Nature Med. 4: 291-297, 1998.
41. **McDonald JW**, Bhattacharyya T, Sensi SL, Lobner D, Ying HS, Canzoniero LMT and Choi DW. Extracellular acidity potentiates AMPA receptor-mediated cortical neuronal death. J. Neurosci. 18: 6290-6299, 1998.
42. **McDonald JW**, Levine JM and Qu Y. Multiple classes of the oligodendrocyte lineage are highly vulnerable to excitotoxicity. NeuroReport 9: 2757-2762, 1998.
43. **McDonald JW**. Repairing the damaged spinal cord. Scientific American, 281(3): 64-73, 1999.
44. Behrens MM, Strasser U, Heidinger V, Lobner D, Yu S-P, **McDonald JW**, Won M and Choi DW. Selective activation of group II mGluRs with LY354740 does not prevent neuronal excitotoxicity. Neuropharmacol. 38:1621-1630, 1999.
45. **McDonald JW**, Liu X-Z, Qu Y, Liu S, Turetsky D, Mickey SK, Gottlieb DI and Choi, DW. Transplanted embryonic stem cells survive, differentiate, and promote recovery in injured rat spinal cord. Nature Med., 5:1410-1412, 1999.

46. Liu S, Qu Y, Stewart T, Howard M, Chakraborty S, Hlekamp T, **McDonald JW**. Embryonic stem cells differentiate into oligodendrocytes and myelinate in culture and after spinal cord transplantation. Proceedings of the National Academy of Sciences, 97: 6126-6131, 2000.
47. Grill WM, **McDonald JW**, Peckham PH, Heetderks W, Kocsis J, Weinrich M. At the interface: Convergence of neural regeneration and neural prostheses for restoration of function. J. Rehabilitation Research and Development, 38: 633-639, 2001.
48. Corbetta M, Burton H, Sinclair RJ, Conturo TE, Akbudak E, **McDonald JW**. Functional reorganization and stability of somatosensory-motor cortical topography in a tetraplegic subject with late recovery. Proceed of the Nat Acad of Sciences of the United States of America. 99(26): 17066-71, 2002.
49. **McDonald JW**, Stefovskaja VG, Liu XZ, Shin H, Liu S, Choi, DW. Neurotrophin potentiation of iron-induced spinal cord injury. Neuroscience, 1215(3): 931-939, 2002.
50. Sadowsky C, Volshteyn O, Schultz L, **McDonald JW**. Spinal Cord Injury. Disability & Rehabilitation, 24(13): 680-687, 2002.
51. **McDonald JW**, Becker D, Sadowsky CL, Jane JA Sr, Conturo TE, Schultz LM. Late Recovery following Spinal Cord Injury. Case Report and Review of the Literature (erratum appears in J Neurosurg, 97(3 Suppl): 405-406, 2002). Journal of Neurosurgery, 97(2 Suppl): 252-265, 2002.
52. **McDonald JW**, Sadowsky C. Spinal Cord Injury: Doable Therapeutics. Lancet, 359: 417-425, 2002.
53. **McDonald JW** and Howard MJ. Repairing the damaged spinal cord: a summary of our early success with embryonic stem cell transplantation and remyelination. Prog Brain Res. 137: 299-309. Review, 2002.
54. Becker D, Sadowsky CL, **McDonald JW**. Restoring Function after Spinal Cord Injury. Neurologist, 9(1): 1-15, 2003.
55. Leuchtmann EA, Ratner AE, Vijitruth R, Qu Y, Farhangrazi ZS and **McDonald, JW**. AMPA Receptors are the Major Mediators of Excitotoxic Death in Mature Oligodendrocytes. Neurobiology of Disease, 14(3): 336-348, 2003.
56. Dong H, Fazzaro A, Xiang C, Korsmeyer S, Jacquin MF, **McDonald JW**: Enhanced oligodendrocyte survival after spinal cord injury in Bax-deficient mice and mice with delayed Wallerian degeneration. J. of Neurosci. 23(25): 8682-91, 2003.

57. **McDonald JW, Becker D.** Spinal Cord Injury: Promising Interventions and Realistic Goals. American Journal of Physical Medicine & Rehabilitation, 82(10 Suppl): S38-49, 2003.
58. **McDonald JW, Becker D, Holekamp TF, Howard M, Liu S, Lu A, Lu J, Platik MM, QU Y, Stewart T, Vadivelu S:** Repair of the injured spinal cord and the potential of embryonic stem cell transplantation. J. of Neurotrauma 21(4):383-393, 2004.
59. **Qu Y, Vadivelu S, Choi L, Liu S, Lu A, Lewis B, Girgis R, Snider BJ, Choi DW, Gottlieb DI, McDonald JW.** Neurons Derived from Embryonic Stem (ES) Cells Resemble Normal Neurons in their Vulnerability to Excitotoxic Death. Exp Neurol., 184(1): 326-36, 2003.
60. **Myckatyn T, Mackinnon S, McDonald JW.** Stem cell transplantation and other novel techniques for promoting recovery from spinal cord injury. Transplant Immunology, special edition journal, in press.
61. **Kerr D and The Transverse Myelitis Consortium Working Group.** Proposed Diagnostic Criteria and Nosology of Acute Transverse Myelitis. Neurology, in press.
62. **Vadivelu S, Platik MM, Choi L, Lacy ML, SAR, Qu Y, Holekamp TF, Becker D, Gottlieb DI, Gidday JM, McDonald JW.** Multi-germ layer lineage CNS repair: Transplanted embryonic stem cells generate both nerve cells and vascular cells in the injured brain. Journal of Neuroscience, submitted.
63. **Vadivelu S, Platik MM, Lacy ML, Shah AR, Holekamp TF, Becker D, Gottlieb DI, Gidday JM, McDonald JW.** Transplanted embryonic stem cells contribute to multi-lineage CNS organ repair. PNAS, submitted.
64. **Ratner AE, Howard MJ, Leuchtmann EA, Qu Y, Farhangrazi ZS, Levine JM, McDonald JW.** Oligodendrocyte Progenitor Cells are Highly Vulnerable to Excitotoxicity, Mediated by AMPA but not Kainate Receptors, Glia, resubmitted 04-22-02.
65. **Husan A, Qu Y, McDonald JW.** Intrathecal ES-Cell transplantation: Self-organization into CNS-like tissue with features resembling normal spinal cord. Nature Biotechnology, submitted.
66. **Rosenzweig ES, McDonald JW.** Rodent models for treatment of spinal cord injury: Research trends and progress toward useful repair. Current Opinion in Neurology, Vol. 17, 2004, in press.

67. Dilmanian FA, Qu Y, Lenihan D, Liu S, Steidinger T, Gilbert J, Yakupov R, Sze CI, **McDonald JW**. Targeted and selective demyelination with minima axonal damage induced by high-dose synchrotron-generated x-ray microbeams. *GLIA*, submitted May, 2004.

68.

Invited Reviews, Letters and Refereed Reviews:

**McDonald JW** and Johnston MV. Physiological and pathophysiological roles of excitatory amino acids during central nervous system development. *Brain Res. Rev.*, 15: 41-70, 1990.

**McDonald JW** and the Research Consortium of the Christopher Reeve Paralysis Foundation. Repairing the Damaged Spinal Cord. *Scientific American*, September: 64-73, 1999.

**McDonald JW**, Gottlieb DI and Choi DW. Reply to "What is a functional recovery after spinal cord injury?" *Nature Med.*, 6:358, 2000.

**McDonald JW**. ES cells and Neurogenesis. In *Stem Cells and CNS Development*. M. Rao (Ed), The Human Press Inc., Totowa, NJ, pp. 207-261, 2001.

**McDonald JW**, Grill WM, Heetderks W, Kocsis J, Weinrich M, Peckham PH. At The Interface: Convergence of Neural Regeneration and Neural Prostheses for Restoration of Function. *Journal of Rehabilitation Research & Development*, 38:633-639, 2001.

**McDonald JW**. Spinal Cord Injury and Repair. In *Diseases of the Nervous System: Clinical Neurosciences and Therapeutic Principles*, 3<sup>rd</sup> Ed., in press.

**McDonald JW**, Sadowsky C. Spinal Cord Injury: Doable Therapeutics. *Lancet*, 359:417-425.

Kerr D and The Transverse Myelitis Consortium Working Group. Proposed Diagnostic Criteria and Nosology of Acute Transverse Myelitis. *Neurology*, in press.

**McDonald JW** and Howard MJ. Repairing the Damaged Spinal Cord: A Summary of Our Early Success with Embryonic Stem Cell Transplantation and Remyelination. *Progress in Brain Research*. 137: 299-309, 2002

Sadowsky C, Volshteyn O, Schultz L, **McDonald JW**. Rehabilitation in Practice: Spinal cord injury. *Disability and Rehabilitation*, 24(13): 680-687, 2002.

Chapters in Books and Other Non-refereed Materials:

1. **McDonald JW**, Silverstein FS, Cardona D, Uckele J, Chen R and Johnston MV. Neuroprotective effects of MK-801 and other compounds on perinatal hypoxic-ischemic injury. In Sigma Opioid-PCP like Compounds As Molecular Probes in Biology. E.F. Domino and K.M. Kamenka (Eds.), NPP Press, pp. 697-708, 1988.
2. Johnston MV, **McDonald JW** and Silverstein FS. Role of synaptic mechanisms in hypoxic-ischemic brain injury and birth defects. In J.W. Swann (Ed.), Disorders of the Developing Nervous System: Changing Views on Their Origins, Diagnoses and Treatments, Alan & Liss, New York, pp. 69-92, 1988.
3. **McDonald JW**, Silverstein FS and Johnston MV. Comparison of neuroprotective effects of competitive and non-competitive NMDA antagonists against NMDA mediated neurotoxicity in an in vivo perinatal rat model. In Recent Advances in Excitatory Amino Acid Research. E.A. Cavalheiro, J. Lehmann, L. Turski (Eds.), Neurology and Neurobiology, Vol. 46, Alan R. Liss, New York, pp. 601-604, 1988.
4. **McDonald JW**, Trescher WH and Johnston MV. The pattern and degree of selective vulnerability to excitotoxic brain injury is dependent upon developmental age. In Excitatory Amino Acids, Vol 5. B.S. Meldrum, F. Moroni, R.P. Simon and J.H. Woods (Eds.), Raven Press, New York, pp. 609-614, 1991.
5. Johnston MV, **McDonald JW**, Chen C-K and Trescher WH. Role of Excitatory amino acid receptors in perinatal hypoxic-ischemic brain injury. In Excitatory Amino Acids, Vol 5. B.S. Meldrum, F. Moroni, R.P. Simon and J.H. Woods (Eds.), Raven Press, New York, pp. 711-716, 1991.
6. **McDonald JW** and Johnston MV. Excitatory amino acid neurotoxicity in the developing brain. In NIDA Research Monograph Series- Sigma, PCP, and NMDA receptors, Vol. 133. E.B. DeSouza, D. Clouet, E.D. London (Eds.), National Institute on Drug Abuse, Maryland, pp. 185-205, 1993.
7. Johnston MV and **McDonald JW**. Metabolic and pharmacologic consequences of seizures. In Pediatric Epilepsy, Diagnosis and Therapy. WE Dodson and JM Pellock (Eds), Demos Publication, New York, pp 27-35, 1993.
8. **McDonald JW** and Choi DW. Why Oligodendrocytes Die in Spinal Cord Injury. Brain Works, Dana Publications, 7 (2), 1997.
9. **McDonald JW** and the Research Consortium of the Christopher Reeve Paralysis Foundation. Repairing the Damaged Spinal Cord. Scientific American, September, pp 64-73, 1999.

10. **McDonald JW.** Spinal Cord Injury and Repair. In Diseases of the Nervous System: Clinical Neurosciences and Therapeutic Principles, 3<sup>rd</sup> Ed., in press.

### Abstracts and Presentations:

1. **McDonald JW**, Parnisari RM, Camel JE and Greenough WT. Environmental conditions modulate degeneration and new dendrite growth in cerebellum of senescent rats. Clinical Research, February, 1986.
2. **McDonald JW**, Parnisari RM and Greenough WT. Environmental conditions modulate degeneration and new dendrite growth in cerebellum of senescent rats. The Midwest Student Medical Research Form XVII, February, 1986.
3. Johnston MV, Silverstein FS, Barks J, **McDonald JW**, Young AB, Penney J and Greenamyre JT. Reorganizing glutamate pathways in the developing brain may provide a substrate for hypoxic-ischemic neuronal injury. Sigma opioid-PCP like compounds as molecular probes in biology. July, 1987.
4. **McDonald JW**, Silverstein FS, and Johnston, MV. The glutamate antagonist MK-801 attenuates perinatal hypoxic-ischemic brain injury. Child Neurology Society, October, 1987. Ann. Neurol. 22:407, 1987.
5. **McDonald JW**, Silverstein FS, Cardona D and Johnston MV. The glutamate antagonist MK-801 blocks hypoxic-ischemic brain necrosis in immature rats. Society for Neurosci. Abst. 13:300.14, 1987.
6. **McDonald JW**, Silverstein FS and Johnston MV. 3H-TCP binding hypoxic-ischemic brain, The Society for Pediatric Research, 1988.
7. **McDonald JW**, Silverstein FS and Johnston MV. The glutamate antagonist MK-801 blocks N-methyl-D-aspartate mediated neurotoxicity in immature brain. American Academy of Neurology, April, 1988.
8. **McDonald JW**, Silverstein FS and Johnston MV. Systemic administration of MK-801 protects against N-methyl-D-aspartate (NMDA) and quisqualate (QA) mediated neurotoxicity in perinatal rats. Mich. chapter Neurosci Meeting, March, 1988.
9. **McDonald JW**, Silverstein FS and Johnston MV. NMDA neurotoxicity in 7 d.o. rats offers an in vivo model to rapidly screen neuroprotective drugs: Neuroprotective effects of MK-801 and related compounds. Neurochemistry International, 12(1):37, 1988.
10. **McDonald JW**, Silverstein FS and Johnston MV. Developmental alteration in NMDA receptor/channel binding characteristics and its relationship to neurotoxicity in immature brain. Child Neurology Society, Halifax, Nova Scotia, September 1988.



11. **McDonald JW**, Penney JB, Johnston MV and Young AB. Quantitative autoradiography of [3H]-glycine binding to the glycine receptor associated with the NMDA receptor operated channel. Society for Neurosci. Abst. 14:199.10, 1988.
12. Johnston MV, Silverstein FS and **McDonald JW**. MK-801 pretreatment enhances NMDA mediated brain injury and alters NMDA receptor and PCP receptor binding characteristics in perinatal rats. Society for Neurosci. Abst. 14:299.11, 1988.
13. Silverstein FS, **McDonald JW** and Johnston MV. 3H-TCP binding in hypoxic-ischemic brain. Society for Neuroscience Abst. 14:169.3, 1988.
14. **McDonald JW**. Neuroprotective effects of NMDA receptor antagonists in two models of brain injury. Cambridge Neuroscience, April 1988, lecture.
15. **McDonald JW**, Silverstein FS and Johnston MV. NMDA receptor binding is increased acutely in rats treated with the non-competitive NMDA receptor antagonist MK-801. University of Michigan Student Medical Research Forum, Ann Arbor, MI, October, 1988.
16. **McDonald JW**, Young AB and Johnston MV. The role of the NMDA receptor/channel complex in neuronal injury. Program and Proceedings of MSTP Scientific Retreat, 42-46, 1988.
17. **McDonald JW**, Garofalo EA, Hood T, Sackellares C and Johnston MV. Distribution of excitatory amino acid and GABA receptor binding in hippocampus of patients with epilepsy. American Academy of Neurology Abst. 1989, in press.
18. Uckele J, **McDonald JW**, Johnston MV and Silverstein FS. Glycine antagonists attenuate NMDA mediated brain injury. Soc. Ped. Res. Absts. 1989, in press.
19. **McDonald JW**. Roles of excitatory amino acid neurotransmitters in the physiology and pathophysiology of brain development. Johns Hopkins School of Medicine, lecture.
20. Uckele JE, **McDonald JW**, O'Mara K, Silverstein FS and Johnston MV. Chronic MK-801 treatment enhances NMDA recognition site binding in perinatal rats. Soc. Neurosci. Abst. 15:86.2, 1989.
21. **McDonald JW**, Johnston MV and Young AB. Ontogeny of the receptors comprising the NMDA receptor complex. Soc. Neurosci. Abst. 15:86.3, 1989.
22. Johnston MV, **McDonald JW**, Hood T, Sakellares C, Garofalo E, McKeever PE, Troncoso J and Gilman S. Elevated NMDA receptor and reduced GABA receptor

- binding in hippocampus from patients with temporal lobe epilepsy. Soc. Neurosci. Abst. 15:478.14, 1989.
23. **McDonald JW**, Hood T, Sackellares J, Garofalo E, Khahil B, McKeever P, Gilman S, Troncoso J and Johnston MV Temporal Lobe Epilepsy: Excitatory and inhibitory amino acid receptor binding changes in excised hippocampus. Epilepsia 30:719, 1989.
  24. **McDonald JW**, Trescher WH and Johnston MV. The pattern and degree of selective vulnerability to excitotoxic brain injury in vivo is dependent upon developmental age. Neurochem. Intn'l. 16 (suppl. 1):53, 1990.
  25. **McDonald JW**, Trescher WH and Johnston MV. Developmental changes in the susceptibility to excitotoxic brain injury. Plasticity and pathology in the damaged brain. UCSD, San Diego, CA, February 9-10, 1990.
  26. Trescher WH, **McDonald JW** and Johnston MV. Variation in nutritional state alters susceptibility to NMDA induced brain damage. Pediatric Res. 27(4):350A, 1990.
  27. **McDonald JW**, Shapiro SM, Silverstein FS and Johnston MV. Excitatory amino acid neurotransmitter systems contribute to the pathophysiology of bilirubin encephalopathy. Child Neurology Society, Atlanta, GA, November 1990.
  28. Trescher WH, **McDonald JW** and Johnston MV. Dextrophan and dextromethorphan are partially neuroprotective against NMDA induced brain injury in neonatal rats. Annals Neurol. 28(3):413, 1990.
  29. Johnston MV, **McDonald JW** and Trescher WH. Neuroprotective pharmacology of AMPA and quisqualate induced brain injury. Soc. Neurosci. Abst. 16:89.8, 1990.
  30. **McDonald JW**, Shapiro SM, Silverstein FS and Johnston MV. Hyperbilirubinemia is associated with enhanced susceptibility to excitotoxic brain injury. Soc. Neurosci. Abst. 16:461.11, 1990.
  31. Trescher WH, **McDonald JW** and Johnston MV. Sensitivity to AMPA induced brain injury transiently peaks early in postnatal development. Soc. Neurosci. Abst. 16:461.10, 1990.
  32. Chen C-K, **McDonald JW**, Trescher WH and Johnston MV. MK-801 transiently decreases cerebral temperature in perinatal rats. Soc. Neurosci. Abst. 16:89.9, 1990.

33. Trescher WH, **McDonald JW** and Johnston MV. Variation in nutritional status alters susceptibility to NMDA induced brain damage in neonatal rats. Pediatric Res. 27:350A, 1990
34. Hamosh A, Johnston MV, **McDonald JW**, Francomano C, Niedermeyer E and Valle D. One-year experience with combination benzoate and excitatory amino acid antagonist therapy for non-ketotic hyperglycinemia. Annals Neurol. 30:469, 1991.
35. Vartaniam MG, **McDonald JW** and Taylor CP. In vivo neuroprotective and anticonvulsant actions of 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo (F) quinoxaline (NBQX). Soc. Neurosci. 17:108.8, 1991.
36. Blue ME, **McDonald JW** and Johnston MV. Ontogeny of excitatory amino acid receptors in barrel field cortex of immature rat. Soc. Neurosci. 17:248.8, 1991.
37. Trescher WH, **McDonald JW** and Johnston MV. Neuroprotective pharmacology and ontogeny of quinolinate induced injury in developing brain. Soc. Neurosci. 17:536.19, 1991.
38. Cline HT, **McDonald JW** and Constantine-Paton. Glutamate receptor binding in the frog brain. Soc. Neurosci. Abst. 17:317.10, 1991
39. Trescher WT, **McDonald JW** and Johnston MV. Neuroprotective pharmacology and ontogeny of quinolinate-induced brain injury in immature rat. Annal Neurol. 30:481-482, 1991.
40. **McDonald JW**, Schoepp DD and Johnston MV. Neuroprotective synergism of 2-amino-3-phosphono-propionate (D,L-AP3) and MK-801 against ibotenate induced brain injury. Proceedings Excitatory Amino Acids 1992, Yosemite, CA, February 16-21, 1992.
41. Schoepp DD, Lunn WHW, Salhoff CR and **McDonald JW**. The NMDA agonist D,L-(tetrazol-5-yl)glycine is an extremely potent in vivo excitotoxin. Soc. Neurosci. 18:571.15, 1992.
42. **McDonald JW** and Schoepp DD. Aminooxyacetic acid (AOAA) potentiates excitotoxic brain injury in perinatal rats. Soc. Neurosci. 18:192.5, 1992.
43. Gidday JM, Fitzgibbons JC, Shah AR, Thurston JH, Park TS and **McDonald JW**. Preconditioning does not provide cerebroprotection from intrastriatal injections of AMPA or NMDA. Soc. Neurosci. 20:427.5, 1994.
44. **McDonald JW** and Schoepp DD. Cyclic-AMP analogues produce excitotoxicity. Soc. Neurosci. 20:628.4, 1994.

45. **McDonald JW**, Goldberg MP, Choi DW and Chi S-I. Cyclosporine-A induces apoptosis in cultured cortical neurons. Annals Neurol. 38:307, 1995.
46. **McDonald JW**, Goldberg MP, Gwag BJ and Choi DW. Cyclosporin-A and okadaic acid induce apoptosis in cultured cortical neurons. Soc. Neurosci. 21:298.13, 1995.
47. Canzoniero LMT, Sensi SL, Ying HS, **McDonald JW**, Muir JK and Choi DW. Extracellular acidity induces apoptosis death of cultured cortical neurons. Soc. Neurosci. 21:89.7, 1995.
48. **McDonald JW**, Bhattacharyya T, Sensi SL, Lobner D, Ying HS and Choi DW. Extracellular acidic pH exacerbates AMPA receptor-mediated neuronal injury. Neurol. 46:A468, 1996.
49. **McDonald JW**, Shah H, Choi DW and Goldberg MP. Cultured murine oligodendrocytes are highly vulnerable to AMPA/kainate receptor-induced death. Soc. Neurosci. 22:478.5, 1996.
50. Dong H-X, Good KE, Goldberg MP, **McDonald JW**, Liu XZ, Xu XM, Hu R, Du C, Zhang SX, Wu YJ, Fan GS, Hsu CY, Choi DW and Jacquin MF. Cell death after spinal contusion: light microscopy. Soc Neurosci. 22:127.4, 1996.
51. **McDonald JW**, Althomsons SP, Hyrc KL, Goldberg MP and Choi DW. Oligodendrocytes are highly susceptible to AMPA/Kainate receptor- and hypoxia-induced death. J. Neurotrauma. 13:599, 1996.
52. **McDonald JW**, Farhangrazi S and Choi DW. Cultured murine cortical oligodendrocytes are highly vulnerable to  $\beta$  -amyloid - induced death. Neurol. 48:A, 1997.
53. **McDonald JW** and Choi DW. Central Pontine Myelinolysis: characterization of a new model. Annals Neurol. 42:427, 1997.
54. **McDonald JW**, Goldberg, MP, Althomsons SP and Choi DW. Adult oligodendrocytes in vivo are highly vulnerable to AMPA-induced excitotoxic death. Soc Neurosci. 23:2305 (900.2), 1997.
55. Althomsons SP, **McDonald JW**, Hyrc KL, Dugan LL, Choi DW and Goldberg MP. AMPA receptor activation mediates hypoxic oligodendrocyte death in vitro. Soc. Neurosci. 23:1381 (540.11), 1997.
56. Althomsons SP, **McDonald JW**, Hyrc KL, Choi DW and Goldberg MP. Oligodendrocyte vulnerability to AMPA receptor-mediated injury depends on culture duration. J. Neurotrauma. 14:779 (85), 1997.

57. **McDonald JW**, Sensi SL, Lobner D, Ying HS, Canzoniero LMT and Choi DW. Extracellular acidity potentiates AMPA receptor-mediated cortical neuronal and oligodendrocyte death. J. Neurotrauma. 14:792 (138), 1997.
58. **McDonald JW**, Qu Y, Tian M, and Choi DW. AMPA receptor mediated excitotoxicity contributes to the selective loss of oligodendrocytes in central pontine myelinolysis. Amer. Acad. Neurol. 50:A257 (S28.001) 1998.
59. Dong HX, Yoon YW, Korsmeyer S, Choi DW, Jacquin MF, and **McDonald JW**. Reduced oligodendrocyte death after spinal cord injury (SCI) in mice deficient in BAX (-/-) or in mice carrying a mutation causing delayed Wallerian degeneration (WLD<sup>8</sup>). Soc. Neurosci. 25:1774 (704.14), 1999.
60. Liu XZ, Majid A, **McDonald JW**, Zipfel G, Lee J-M, and Choi DW. Oligodendrocyte progenitor cells proliferate and differentiate after traumatic spinal cord injury. Soc. Neurosci. 25:1331 (537.8), 1999.
61. **McDonald JW**, Choi DW, Gottlieb DI, Liu XZ, Turetsky D, Liu S, Mickey SK, and Qu Y. Transplanted embryonic stem (ES) cells integrate, differentiate, and promote recovery in injured rat spinal cord. Soc. Neurosci. 25:749 (295.15), 1999.
62. Howard MJ, Liu S, Qu A, Cross A, Xiang C, Jacquin MF and **McDonald JW**. Transplanted embryonic stem cells migrate into the parenchyma of demyelinated and dysmyelinated CNS and may myelinate axons. Soc. Neurosci. 25:749 (295.13), 1999.
63. Liu S, Howard MJ, Stewart TS, Levine JM, and **McDonald JW**. Differentiation, enrichment and purification of oligodendrocytes from cultured embryonic stem cells. Soc. Neurosci. 25:2039 (810.5), 1999.
64. Qu Y, Howard MJ, Liu S, Fox K, Clark J, and **McDonald JW**. Astrocytes cultured from different CNS regions determine the neuronal phenotype developing from cultured embryonic stem cells. Soc. Neurosci. 25:521 (204.1), 1999.
65. Stewart TJ, Liu S, Fox K, Lauryssen C, and **McDonald JW**. Embryonic stem cell derived oligodendrocytes are capable of myelinating many neuronal axons in culture. Soc. Neurosci. 25:749 (295.14), 1999.
66. Howard MJ, Liu S, Stewart TJ, Holekamp TF, Qu Y, and **McDonald JW**. Caspase 3 dependent apoptosis death of embryonic stem cell derived neural cells occurs after dissociation in culture or transplantation into the injured spinal cord, Soc. Neurosci., 26:(327.3), 2000.

67. Qu Y, Howard M, Liu S, Choi DW, and **McDonald JW**. AMPA/KA Receptor mediated excitotoxicity contributes to the selective loss of oligodendrocytes in central pontine myelinolysis, Soc. Neurosci., 26:(856.1), 2000.
68. Holekamp TF, Stewart TJ, Qu Y, Liu S, and **McDonald JW**. Embryonic stem cells can differentiate into a wide variety of neuronal phenotypes, Soc. Neurosci., 26:(312.3), 2000.
69. Liu XZ, Behrens MM, **McDonald JW**, and Choi DW. The antioxidant S-PBN prevents NT 4/5 and BDNF- mediated potentiation of iron-induced injury in rat spinal cord. Soc. Neurosci., 26:(856.8), 2000.
70. Bulte JWM, Lu J, Zywicke H, van Gelderen P, Douglas T, **McDonald JW**, Frank JA. 3D MR Tracking of Magnetically Labeled Embryonic Stem Cells Transplanted in the Contusion Injured Rat Spinal Cord. International Society of Magnetic Resonance in Medicine, Glasgow, Scotland, April, 2000.
71. Qu Y, Schottler F, Liu S, Lu J, Platik M, Clair A, Adams, DS, Gottlieb D, and **McDonald JW**. Line-specific differences in parameters of neural stem cells derived from embryonic stem (ES) cells. Soc. Neurosci., 27: (133.16), 2001.
72. Liu, S, Elbert SS, Elbert F, Schottler F, Bonnot J, Lu A, **McDonald JW**. Embryonic stem (ES) cells produce extensive extracellular matrix (ECM) that is highly supportive for neurite outgrowth. Soc. Neurosci., 27: (133.17), 2001.
73. Schottler F, Qu Y, Platik M, Liu S, Gottlieb DI, Jacquin MF, **McDonald JW**. Organization of neural lineage cells in embryoid bodies derived from murine embryonic stem (ES) cells. Soc. Neurosci., 27: (133.19), 2001.
74. Howard MJ, Chang LK, Schottler F, Clair AM, Adams LD, Liu S, Stewart TJ, Holekamp TF, Jacquin MF, Gottlieb DI, Johnson EM, **McDonald JW**. Apoptotic death of embryonic stem (ES) cell-derived neural cells occurs after dissociation in culture or transplantation into the injured spinal cord: limiting cell death. Soc. Neurosci., 27: (598.1), 2001
75. Lu JJ, Bulte JWM, Liu S, Schottler F, Zywicke H, Van Gelderen P, Howard MJ, Douglas T, Frank JA, **McDonald JW**. MR Tracking of Magnetically Labeled Embryonic Stem Cells Transplanted in the Contusion Injured Rat Spinal Cord Soc. Neurosci., 27: (791.4), 2001
76. S. Dusenbery, B.J. Snider, L.Y. Teel, A. St. Clair, L. Adams, D.I. Gottlieb, S. Liu, **McDonald JW**, D.W. Choi. Neurotrophin Pretreatment Enhances Excitotoxic Death in Neurons Derived from Embryonic Stem Cells. Society For Neuroscience, 2001.

77. Ao H and **McDonald, JW**. Self-assembly of ES cells into neural tissues with features resembling normal spinal cord. Soc. Neurosci., submitted 2002.
78. Li Q, Farhangrazi ZS, **McDonald JW**. Baclofen reduces proliferation/survival of neural stem cells after spinal cord injury (SCI). Soc. Neurosci., submitted 2002.
79. Liu S, Wu YJ, Lu A, Qu Y, Howard M, Farhangrazi ZS, **McDonald JW**. Embryonic stem cell transplantation reduces the macrophage response after spinal cord injury in the rat. Soc. Neurosci., submitted 2002.
80. Martinez CO, Liu S, Qu Y, **McDonald JW**. Embryonic stem cell-derived oligodendrocytes survive, proliferate, and myelinate dorsal root ganglion axons. Soc. Neurosci., submitted 2002.
81. Qu Y, Liu S, Lu A, Farhangrazi ZS, **McDonald JW**. Immunocytochemical and ultrastructural studies of ES cell derived neuronal cultures. Soc. Neurosci., submitted 2002.
82. Becker D, Grill WM, **McDonald JW**. Functional electrical stimulation replenishes the neural progenitor pool in the adult CNS after spinal cord injury. Soc. Neurosci., (245.3), 2003.
83. Vadivelu S, Stewart TJ, Miller JH, Tom V, Liu S, Li Q, Howard MJ, Silver J, **McDonald JW**. Embryonic stem cell transplantation: Penetration of the glial scar and robust axonal regeneration into white matter in the injured adult rat spinal cord. Soc. Neurosci., (245.2), 2003.
84. Schottler FE, Deogun H, Khan A, Higashikubo R, **McDonald JW**. Migration and integration of transplanted embryonic stem cells in demyelinated and undamaged areas of the spinal cord. Soc. Neurosci., (347.9), 2003.
85. Li Q, **McDonald JW**. Dose-dependent effects of Baclofen on progenitor and oligodendrocyte proliferation in rat sci. Soc. Neurosci., (245.21), 2003.
86. Wu YJ, Luo FH, Li Q, Luecking L, Lu A, **McDonald JW**. Quantitation of transplanted mouse ES cells in injured rat spinal cord using real time PCR. Soc. Neurosci., (790.4), 2003.
87. Dilmanian A, Qu Y, Liu S, Hainfeld J, Steidinger T, Sze CI, Yakupov R, **McDonald, JW**. Selective demyelination with minimal axonal or vascular injury induced by high-dose synchrotron-generated x-ray microbeams. Submitted 2004
88. Lu Aiwu, Qu Y, Wu Y, Mijeong K, **McDonald JW**, Huettner JE. Connexon hemichannels and gap junctions in human embryonic stem cells. Internat Society for Stem Cell Research, 2<sup>nd</sup> Annual Meeting, Boston, MA, June 10-13, 2004. Submitted January 16, 2004.

**PATENTS**

U.S. Patent Application No. 09/693,619 filed October 21, 2000

**OLIGODENDROCTYE CELL CULTURES AND METHODS FOR THEIR  
PREPARATION AND USE**

**Our Ref.: WSHU-0015**

**Your Ref.: CKI-0215**





PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of:  
Broyles *et al.*

Serial No.: 10/003,669


Filed: November 1, 2001

For: GENE REGULATION THERAPY  
INVOLVING FERRITIN

Group Art Unit: 1632

Examiner: Janice Li Qian

Atty. Dkt. No.: OMRF:027US/SLH

CERTIFICATE OF MAILING 37 C.F.R. § 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date below:	
May 14, 2004 Date	 Steven L. Highlander

**DECLARATION OF DR. XINLI LIN UNDER 37 C.F.R. §1.132**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450


I, the undersigned, do declare that:

1. I currently hold the position of Executive Vice President and Chief Scientific Officer at ProteomTech, Inc., Emeryville, CA. I have over 20 years of research experience in the fields of molecular, protein and cellular biology. A copy of my *curriculum vitae* is attached.

2. I am familiar with the work of Dr. Robert Broyles relating to ferritin-H as a repressor of the human  $\beta$ -globin gene in erythroid cells – when present in embryonic cells, it represses  $\beta$ -globin, but when absent in adult cells,  $\beta$ -globin is expressed. Thus, ferritin-H appears to be properly characterized as a hemoglobin switching factor.
3. Moreover, I am well aware of the implications this observation has in the treatment of  $\beta$ -globin-related diseases, such as sickle cell anemia. The relevant target cells for this condition (adult erythroid cells) have been shown to express ferritin receptors and to take up exogenously added ferritin protein, and other human cells (astrocytoma cells) which take up exogenous ferritin-H also transport it to the cell nucleus by an active transport mechanism. Thus, using ferritin-H or ferritin-H peptides as a therapeutic agent for treating sickle cell anemia is a logical extension of Dr. Broyles' work.
4. Regarding the feasibility of this approach, protein drugs have been used in clinical settings for several decades. For example, human insulin has been used to treat diabetics, and C-GSF has been used to treat infectious diseases and help to fight cancer. In addition, many other protein drugs have been approved by FDA in recent years, and our own company, which specializes in protein drug development, has many protein drug candidates in the pipeline. Thus, given what is known about the uptake and transport of ferritin-H, this protein is a promising candidate for treating indications such as sickle cell disease.

5. I hereby declare that all statements made herein of my knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

5/12/04  
Date

  
Xinli Lin, Ph.D.

## **CURRICULUM VITAE**

**Name:** Xinli Lin

**Address:** ProteomTech, Inc.  
5980 Horton St., Suite 405  
Emeryville, CA 94608  
Tel: 510-597-9134  
FAX: 510-601-6751  
ProteomTech, Inc.

**Personal data:** Marital status: married  
Children: two

### **Education:**

1987	Ph.D.	Virginia Polytechnic Institute and State University (Virginia Tech). Major: Biochemistry
1982	B.S.	Peking University, Beijing, China. Major: Chemistry

### **Honors:**

1981-1984	Fellowship: CUSBMBEP (China-United States Biochemistry and Molecular Biology Examination Program)
1984-1985	Cunningham Year Fellowship: Virginia Polytechnic Institute and State University
1985	Graduate Student Research Grand Award by GSA: VA Tech
1988	Travel Grant Award for 14th International Congress of Biochemistry by IUB
1992	Merrick Award for Junior Scientist, OMRF
1999-2001	China Bridges International Fellowship Award
2000	Edward L. and Thelma Gaylord Prize for Scientific Achievement

### **Professional and Scientific Memberships:**

American Society for Biochemistry and Molecular Biology.  
American Association for the Advancement of Science.  
American Society of Gene Therapy  
Ray Wu Society

**Research and Professional Experience:**

2001 to Present	Founder, Executive Vice President, Chief Scientific Officer (CSO), ProteomTech, Inc.
2002	Adjunct Member (Professor), OMRF
2000 to 2002	Associate Member, Head, Functional Proteomics Laboratory Director, Protein Expression Core, OMRF
2000 to 2002	Adjunct Associate Professor, Dept. of Pathology, University of Oklahoma Health Science Center (OUHSC)
1991 to 2000	Assistant Member, OMRF
1989 - 1991	Senior Research Scientist, OMRF
1986 - 1989	Associate Research Scientist, OMRF
1982 - 1986	Graduate Research with Dr. R. H. White, Virginia Tech
1981 - 1982	B.S. Thesis Research with Professor Sheng Jin, Dept. Chem., Peking University, Beijing, China

**External Research Support:**

**Current Support:**

- Source:** National Institute of Health #1 R43 CA103181-02  
**TITLE:** Recombinant h-VEGI as an Anticancer Therapeutic  
**PI:** Dan Medynski, Ph.D.  
**Co-PI:** Xinli Lin, Ph.D.  
**Percent of Effort, Dr. Xinli Lin:** 15%  
**Dates and Direct Cost of Entire Project:** 07/01/04 - 06/30/06 \$750,000
- Source:** National Institutes of Health # 1 R43 CA105919-01  
**TITLE:** Recombinant HbxAg Production for Anti-Cancer Therapeutic  
**PI:** Xinli Lin, Ph.D.  
**Percent of Effort, Dr. Xinli Lin:** 15%  
**Dates and Direct Cost of Entire Project:** 05/14/04 - 11/13/04 \$100,000
- Source:** National Institutes of Health # R43 HL075883-01  
**TITLE:** Bioengineering Prourokinase for Improved Fibrinolysis  
**PI:** Dan Medynski, Ph.D.  
**Co-PI:** Xinli Lin, Ph.D.  
**Percent of Effort, Dr. Xinli Lin:** 10%

**Dates and Direct Cost of Entire Project:** 01/01/04 - 06/30/04 \$100,000

**Prior Support:**

**Source:** National Institute of Health #1 R43 CA103181-01

**TITLE:** Recombinant h-VEGI as an Anticancer Therapeutic

**PI:** Dan Medynski, Ph.D.

**Co-PI:** Xinli Lin, Ph.D.

**Percent of Effort, Dr. Xinli Lin:** 15%

**Dates and Direct Cost of Entire Project:** 08/01/03 - 01/31/04 \$100,000

**Source:** NIGMS 1 P50 GM62407-01

**TITLE:** Southeast Collaboratory for Structural Genomics

**PI:** Bi-Cheng Wang, Ph.D., University of Georgia

**Percent of Effort, Dr. Xinli Lin:** 15%

**Dates and Direct Cost of Entire Project for Dr. Lin:** 10/01/00 - 09/30/02 \$300,000

**Source:** National Institutes of Health

**TITLE:** Target-avoidance for HIV protease inhibitors

**PI:** Xinli Lin, Ph.D.

**Percent of Effort:** 15%

**Dates and Direct Cost of Entire Project:** 06/01/99 - 05/31/02 \$347,703

**Source:** Oklahoma Center for the Advancement of Science and Technology (OCAST)

**TITLE:** A Novel Chimeric Vector for *In Vivo* Gene Therapy

**PI:** Xinli Lin, Ph.D.

**Percent of Effort:** 10%

**Dates and Direct Cost of Entire Project:** 10/01/00 - 09/30/02 \$90,000

**Source:** Oklahoma Center for the Advancement of Science and Technology (OARS)

**Title:** Therapy for Cancer Using TK and VHS genes

**PI:** Xinli Lin, Ph.D.

**Percent of Effort:** 10%

**Dates and Direct Costs of the Entire Project:** 10/01/99 - 09/30/01 \$160,000

**Source:** NIH

**PI:** Xue-jun Zhang, PhD.

**Title:** Molecular Basis of Plasminogen-Streptokinase Interaction

**Percent of Effort::** 10%

**Dates and Direct Cost of Entire Project:** 07/01/98 - 06-30-01 \$788,728

**Source:** NIH RO1 AI-CA42500-01

**PI:** Alice Mae Clark, Ph.D.

**CO-PI:** Xinli Lin, Ph.D.

**Title:** Candida Secreted Aspartic Proteases as Drug Targets

**Percent of Effort:** 15%

**Dates and Direct Cost of Entire Project:** 03-01-98 - 02-28-01      \$732,874

**Source:** Oklahoma Center for the Advancement of Science and Technology (OCAST),  
H97-036

**PI:** Xinli Lin, Ph.D.

**Title:** *In Vivo* Gene Delivery in Human Gene Therapy

**Percent of Effort:** 20%

**Dates and direct cost of entire project:** 06-01-97 - 05-31-2000      \$105,000

**Source:** NIH RO1 53585-01

**PI:** Robert A. Floyd, Ph.D.

**Title:** Thiazine Dye Mediated Photokilling of HIV-1 Viruses

**Percent of Effort:** 10%

**Dates and Direct Cost of Entire Project:** 09-30-94 - 10-01-99      \$424,047

National Institutes of Health IR29AI34273 AARD

**TITLE:** *Protease Inhibitor Drugs for Candida Infections*

**PI:** Xinli Lin, Ph.D.

**Percent of Effort:** 50%

**Dates and Direct Cost of Entire Project:** 04/01/93 - 03/31/98      \$349,882

Oklahoma Center for the Advancement of Science and Technology (OCAST)

**TITLE:** *Industrial Application of Thermopsin* AR 2-010

**PI:** Jordan J.N. Tang, Ph.D.

**CO-PI:** Xinli Lin, Ph.D.

**Percent of Effort:** 15%

**Dates and Direct Cost of Entire Project:** 04/01/92 - 03/31/95      \$169,995.

Oklahoma Center for the Advancement of Science and Technology (OCAST)

**TITLE:** *Physiological Functions of Pregnancy-specific Antigen B* HN2-004

**PI:** Xinli Lin, Ph.D.

**Percent of Effort:** 30%

**Dates and Direct Cost of Entire Project:** 06/01/92 - 05/31/95      \$ 90,000

American Heart Association (Oklahoma Affiliate)--OK90G25

**TITLE:** *Decoding the Sorting Signals of the Regulated Secretory Pathway*

**PI:** Xinli Lin, Ph.D.

**Percent of Effort:** 75%

**Dates and Direct Cost of Entire Project:** 07/01/90 - 06/30/93      \$135,000

**Invited Lectures:**

**Lin, X.** Protein engineering on the N- and C-terminal lobes of pepsinogen and pepsin. Sept. 20, 1993. In: *The 5th International Conference on Aspartic Proteinases*, Gifu, Japan, Sept. 19-24, 1993. Organizing Committee Chairman: Dr. Kenji Takahashi, Tokyo University.

**Lin, X.** A series of four lectures for a European Common Market sponsored Advanced Course on "Structure and Function of Aspartic Proteases", which included student training in research techniques of molecular biology and protein engineering. May 23 to June 6, 1994, University of Coimbra, Portugal.

**Lin, X.** Invited to Conference on *Candida* protease and opportunistic infection, University of Mississippi, University, MS, February, 1997.

**Lin, X.** Seminar -- "A new *in vivo* gene delivery system for human gene therapy". Sol Sherry Thrombosis Research Center, Temple University School of Medicine, Philadelphia, PA, September 2, 1997.

**Lin, X.** Seminar series in Beijing, China. Topic: "A new *in vivo* gene delivery system for human gene therapy".

Sept. 10, 1997, Beijing Medical University.

Sept. 16, 1997, Beijing Red Cross Chao Yang University Hospital.

Sept. 19, 1997, Beijing People's University Hospital.

**Lin, X.** The 6<sup>th</sup> Symposium on Life Sciences and Biotechnology. Beijing, China. "Construction of new retroviral producer cells from adenoviral and retroviral vectors", August 7-10, 1998.

**Lin, X.** August 14, 1998, Shenyang Central Hospital, Chinese Medical University, Shenyang, China, "Human gene therapy: the past, the present, and the future".

**Lin, X.** August 20, 1998, Shenyang Central Hospital, Chinese Medical University, Shenyang, China, "Gene expression and functional studies of streptokinase and plasminogen"

**Lin, X.** "Studies on human memapsins". Sept. 11, 1999. In: *The 8th International Conference on Aspartic Proteinases*, Funchal, Madeira, Portugal, Sept. 7-12, 1999. Organizing Committee Chairman: Dr. Carlos Faro, University of Coimbra, Portugal.

**Lin, X.** November 12, 1999. "Identification of memapsin 2 as the beta-secretase that processes the amyloid precursor protein: implications in the treatment of Alzheimer's Disease". College of Life Science, Peking University, Peking, China.

**Lin, X.** July 23, 2000. "Structural Genomics and Functional Proteomics". The 2<sup>nd</sup> RWS Conference. Falmouth, MA.

**Lin, X.** Feb. 13, 2003. "Protein Refolding: from 'Art' to Science". ABRF (The



Association of Biomolecular Resource Facilities) 2003 Meeting, Denver, CO.

Lin, X. Oct. 5, 2003. "Automated High-Throughput Refolding Using a PTR Machine". CBA 8<sup>th</sup> Annual Conference, Rockville, MD.

#### **Patents:**

1. Co-Inventor of Thermopsin - Patent No. 5,215,907, Issued June 1, 1993.  
*Title:* Thermostable Acid Protease from *Sulfolobus acidocaldarius*.
2. Co-Inventor of Vectors for Human *in vivo* Gene Therapy – U.S. Patent No. 6,303,380, Issued Oct. 16, 2001.  
*Title:* Construction of Retroviral Producer Cells from Adenoviral and Retroviral Vectors.
3. Co-Inventor of Napsin, A new human aspartic protease. – U.S. Patent No. 6,225,103. Issued May 1, 2001.  
*Title:* "Cloning and Characterization of Napsin, an Aspartic Protease"
4. Co-Inventor of recombinant memapsin 2. – U.S. patent No. 6,545,127  
*Title:* "Catalytically Active Recombinant Memapsin and Methods of Use Thereof".
5. Inventor of ProteomTech's core technology. – U.S. patent No. 6,583,268  
*Title:* "Universal procedure for refolding recombinant proteins".
6. Co-Inventor of streptokinase/plasmin structure  
*Title:* Thrombolytic Agents Derived from Streptokinase. Patent Pending.
7. Co-Inventor of plasminogen-based plasminogen activator  
*Title:* Human Plasminogen Activator. Patent Pending
8. Inventor of pro-urokinase refolding.  
*Title:* Methods for production of recombinant urokinase
9. Inventor of VEGI-192a refolding, patent in preparation

#### **Publications:**

1. Lin, X., and White, R.H. (1986) "Occurrence of coenzyme F420 and its -mono-glutamyl derivative in nonmethanogenic archaebacteria". *J. Bacteriol.* 168:444-448.

2. Lin, X., and White, R.H. (1987) "Structure of sulfohalopterin-2 from *Halobacterium marismortui*". *Biochemistry*. 26:6211-6217.
3. Lin, X. (1987) "Isolation and characterization of new pterins from nonmethanogenic archaeobacteria". Ph.D. Thesis, Virginia Polytechnic Institute and State University.
4. Lin, X., and White, R.H. (1988) "Structure of sulfapterin (erythroneopterin-3'-D-2-deoxy-2-aminoglucopyranoside) isolated from the thermophilic archaeobacteria *Sulfolobus sulfataricus*". *J. Bacteriol.* 170:1396-1398.
5. Lin, X., and White, R.H. (1988) "Distribution of charged pterins in nonmethanogenic archaeobacteria". *Arch. Microbiol.* 150:541-546.
6. Lin, X., Wong, R.N.S., and Tang, J. (1989) "Synthesis, purification, and active site mutagenesis of recombinant porcine pepsinogen". *J. Biol. Chem.* 264:4482-4489.
7. Lin, X., and Tang, J. (1990) "Purification, characterization, and gene cloning of thermopsin, a thermostable acid protease from *Sulfolobus acidocaldarius*". *J. Biol. Chem.* 265:1490-1495.
8. Fusek, M., Lin, X., and Tang, J. (1990) "Enzymic properties of thermopsin". *J. Biol. Chem.* 265:1496-1501.
9. Lin, X., Fusek, M., Chen, Z., Koelsch, G., Han, H.-P., Hartsuck, J.A., and Tang, J. (1991) "Studies on pepsin mutagenesis and recombinant rhizopuspepsinogen". In: "Aspartic Proteases" (ed., Ben M. Dunn) Plenum Press, New York, NY, pp. 1-8.
10. Lin, X., Fusek, M., and Tang, J. (1991) "Thermopsin, a thermostable protease from *Sulfolobus acidocaldarius*". In: "Aspartic Proteases" (ed., Ben M. Dunn) Plenum Press, New York, NY, pp. 255-257.
11. Lowther, W.T., Chen, Z., Lin, X.L., Tang, J., and Dunn, B.M. (1991) "Substrate specificity study of recombinant *Rhizopus chinensis* aspartic proteinase". *Adv. Exp. Med. Biol.* 306:275-279.
12. Chen, Z., Koelsch, G., Han, H.-P., Wang, X.-J., Lin, X., Hartsuck, J.A., and Tang, J. (1991) "Recombinant rhizopuspepsinogen". *J. Biol. Chem.* 266:11718-11725.
13. Lin, Y.-Z., Fusek, M., Lin, X.L., Hartsuck, J.A., Kezdy, F.J., and Tang, J. (1992) "pH Dependence of kinetic parameters of pepsin, rhizopuspepsin, and their active-site hydrogen bond mutants". *J. Biol. Chem.* 267:18413-18418.
14. Lin, X.L., Lin, Y.-Z., Koelsch, G., Gustchina, A., Wlodawer, A., and Tang, J. (1992) "Enzymic activities of two-chain pepsinogen, two-chain pepsin, and the amino-terminal lobe of pepsinogen". *J. Biol. Chem.* 267:17257-17263.
15. Lin, X.L., Liu, M.T., and Tang, J. (1992) "Heterologous expression of thermopsin, a heat

stable acid proteinase". *Enzyme Microb. Technol.* 14:696-701.

16. Tang, J., Lin, Y., Co, E., Hartsuck, J.A., and Lin, X.L. (1992) "Understanding HIV protease: Can it be translated into effective therapy against AIDS?" *Scand. J. Clin. Lab. Invest.* 52(210):127-135.
17. Lin, X.L., Dashti, A., Schinazi, R.F., and Tang, J. (1993) "Intracellular diversion of glycoprotein gp160 of human immunodeficiency virus to lysosomes as a strategy of AIDS gene therapy". *FASEB J.* 7:1070-1080.
18. Lin, X., Loy, J.A., Sussman, F., and Tang, J. (1993) "Conformational instability of the N- and C-terminal lobes of porcine pepsin in neutral and alkaline solutions". *Prot. Sci.* 2:1383-1390.
19. Lin, X., Tang, J., Koelsch, G., Monod, M., and Foundling, S. (1993) "Recombinant candidropsin, an extracellular aspartic protease from yeast *Candida tropicalis*". *J. Biol. Chem.* 268:20143-20147.
20. Lin, X., Lin, Y., and Tang, J. (1994) "Relationships of human immunodeficiency virus protease with eukaryotic aspartic protease". *Methods Enzymol.* 241:195-224.
21. Tang, J., and Lin, X. (1994) "A new anti-HIV gene therapy strategy -- diversion of gp160 to lysosomes". *Int. Antiviral News* 2:19-20.
22. Tang, J., and Lin, X. (1994) "Engineering aspartic proteases to probe structure and function relationships". *Current Opinions in Biotechnology* 5:422-427.
23. Lin, Y.-Z., Lin, X., Hong, L., Foundling, S., Heinrikson, R.L., Thaisrivongs, S., Leelamanit, W., Ratterman, D., Shah, M., Dunn, B.M., and Tang, J. (1995) "Effect of point mutations on the kinetics and the inhibition of human immunodeficiency virus type 1 protease: relationship to drug resistance". *Biochemistry* 34:1143-1152.
24. Lin, X., Koelsch, G., Loy, J., and Tang, J. (1995) "Rearranging the domains of pepsinogen". *Prot. Sci.* 4:159-166.
25. Rowell, J.F., Ruff, A.L., Guarnieri, F.G., Staveley-O'Carroll, K., Lin, X., Tang, J., August, J.T., and Siliciano, R.F. (1995) "Lysosome-associated membrane protein-1-mediated targeting of the HIV-1 envelope protein to an endosomal/lysosomal compartment enhances its presentation to MHC class II-restricted T cells". *J. Immunol.* 155:1818-1828.
26. Lin, X., and Tang, J. (1995) "Rearranging pepsinogen and pepsin by protein engineering". In: *Aspartic Proteinases: Structure, Function, Biology, and Biomedical Implications*, (Kenji Takahashi, ed.), Plenum Press, New York, pp 33-40.
27. Lin, X., and Tang, J. (1995) Thermopsin. *Methods Enzymol.* 248:156-168.
28. Ermolieff, J., Lin, X., and Tang, J. (1997) Kinetic properties of saquinavir-resistant mutants of human immunodeficiency virus type 1 protease and their implications in drug resistance *in vivo*. *Biochemistry* 36:12364-12370.

29. Reed, D.J., Lin, X., Thomas, T.D., Birks, C.W., Tang, J., and Rother, R.P. (1997) "Alteration of glycosylation renders HIV sensitive to inactivation by normal human serum". *J. Immunol.* **159**:4356-4361.
30. Tang, J., and Lin, X. (1998) "Thermopsin". In: *Handbook of Proteolytic Enzymes*, A. (Barrett *et al.*, eds.), Academic Press, London, pp 980-982..
31. Ermolieff, J., Lin, X., and Tang, J. (1998) "The effect of substrates on the kinetics and the *in vivo* threshold activity of mutant HIV-proteases". *Adv. Exptl. Med. & Biol.* **436**:47-51
32. Koelsch, G., Loy, J., Lin, X., Tang, J. (1998) "Activation mechanism of pepsinogen as compared to the processing of HIV protease gag-pol precursor protein". *Adv. Exp. Med. Biol.* **436**:245-252.
33. Koelsch, G., Tang, J., Monod, M., Foundling, S.I., Lin, X (1998) "Primary substrate specificities of secreted aspartic proteases of *Candida albicans*". *Adv. Exp. Med. Biol.* **436**:335-338.
34. Faro, C., Ramalho-Santos, M, Verissimo, P., Pissarra, J., Frazao, C., Costa, J., Lin X.L., Tang, J., Pires, E. (1998) "Structural and functional aspects of cardosins". *Adv. Exp. Med. Biol.* **436**:423-433.
35. Wang, X., Lin, X., Lowy, J.A., Tang, J., Zhang, X.C. (1998) "Crystal structure of the catalytic domain of human plasmin complexed with streptokinase", *Science*. **281**:1662-1665.
36. Lin, X. (1998) "Construction of new retroviral producer cells from adenoviral and retroviral vectors". *Gene Therapy*. **5**:1251-1258.
37. Faro C, Ramalho-Santos M, Vieira M, Mendes A, Simoes I, Andrade R, Verissimo P, Lin X, Tang J, Pires E (1999) "Cloning and Characterization of cDNA Encoding Cardosin A, an RGD-containing Plant Aspartic Proteinase." *J Biol Chem* **274**(40):28724-28729
38. Wang, X., Jiang, L., Lei, Z., Lin, X. (1999) "The Experiment of HSV-tk Gene Therapy for Gastric Carcinoma *in vitro*." (Chinese) *Chinese Journal of Biochemistry and Molecular Biology*. **15**(6):983-986
39. Wang, X., Terzyan, S., Tang, J., Loy, J., Lin, X., and Zhang, X. (2000) "Human plasminogen catalytic domain undergoes a novel conformational change upon activation" *J. Mol Biol.* **295**(4):903-914.
40. Lin, X., Koelsch, G., Wu, S., Downs, D., Dashti, A., and Tang, J. (2000) "Human aspartic protease memapsin 2 cleaves the  $\beta$ -secretase site of  $\beta$ -amyloid precursor protein. *Proc Natl Aca Sci.* **97**(4):1456-1460
41. Ghosh, A. K., Shin, D., Downs, D., Koelsch, G., Lin, X., Ermolieff, J., Tang, J. (2000) "Design of potent inhibitors form human brain memapsin 2 ( $\beta$ -secretase)" *J. Amer. Chem. Soc.*, **122**:3522-3523.

42. Koelsch, G., Tang, J., Loy, J.A., Monod, M., Jackson, K., Foundling, S.I., and Lin, X. (2000) "Enzyme characterization of secreted aspartic proteases of *Candida albicans*". *Biochimica et Biophysica Acta*, 1480:117-131.
43. Hong L., Koelsch G., Lin X., Wu S., Terzyan S., Ghosh A., Zhang X., Tang J. (2000) "Structure of Memapsin 2 ( $\beta$ -secretase) complexed with inhibitor: a template to design drugs for Alzheimer's Disease" *Science*, 290:150-153.
44. Wang, X., Wu, S., Wei, X., Lin, X. (2000) "The cloning, expression, and refolding of TNF-related apoptosis inducing ligand" (Chinese). *Journal of Beijing Medical University*, 32(5):387-390.
45. Wang, XJ, Wang, X., Wei, X., Lei, Z., Lin, X. (2000) "Construction of recombinant adenovirus (Ad-HSVtk) for tumor gene therapy" (Chinese). *China Science Abstract*, 6(10):1274-1277.
46. Wang, XJ, Wang, X., Zhang, L., Wei, X., Lin, X. (2000) "Adenovirus-mediated gene therapy of human gastric carcinoma by Herpes Simplex Virus-thymidine kinase *in vitro*" (Chinese). *China Science Abstract*, 6(10):1278-1281.
47. Wei, X., Wang, X., Zhang, L., Chen, K., Liang, Y., Lin, X. (2000) "The establishment and effect of Tet-regulated expression system of TRAIL on gastric carcinoma cell line" (Chinese). *China Science Abstract*, 6(10):1282-1284.
48. Wei, X., Lin, X., Wang, X. (2001) "TNF-related apoptosis inducing ligand and its research progress on cancer treatment" (Chinese). *Physiology Science Progress*, 32(1):18-22.
49. Zhang, J., Wang, X., Zhang, L., Xu, J., Wang, XJ., Lin, X. (2001) "The anti-tumor effect of GM-CSF-tk fusion gene in human neuroblastoma cell line SH-SY5Y" (Chinese). *Journal of Peking University (Health Sciences)*, 33(1): 62-65.
50. Zhang, J., Wang, X., Zhang, L., Xu, J., Wang, XJ., Lin, X. (2001) "The anti-tumor effect of GM-CSF-tk fusion gene in human neuroblastoma cell line SH-SY5Y" (Chinese). *Journal of Peking University (Health Sciences)*, 33(1): 62-65.
51. Loy, A., Lin, X., Schenone, M., Castellino, F.J., Zhang, X., and Tang, J. (2001) "Domain interactions between streptokinase and human plasminogen", *Biochemistry*. 4;40(48):14686-95.
52. Yong-Tae Kim, Deborah Downs, Shili Wu, Azar Dashti, Yujun Pan, Peng Zhai, Xinjuan Wang, Xuejun C. Zhang and Xinli Lin. (2002) "Enzymic Properties of Recombinant BACE2". *Eur. J. Biochem.* 269:1-11.
53. Pan, Yujun, Peng, Z., Dashti, A., Wu, S., Lin, X., Wu, M. (2002) "A Combined Delivery by Co-transduction of Adenoviral and Retroviral Vectors for Cancer Gene Therapy". *Cancer*

**Abstracts and Presentations:**

1. Tang, J., Wong, R.N.S., Lin, X.L., Delaney, R., and Wang, X.-J. (1988) Molecular cloning and expression of aspartic protease zymogens. 18th Linderstrom-Lang Conference, Elsinore, Denmark.
2. Lin, X.L., Wong, R., and Tang, J. (1988) cDNA Cloning, expression and site-directed mutagenesis of porcine pepsinogen in *Escherichia coli*. 14th International Congress of Biochemistry, Prague, Czechoslovakia.
3. Lin, X.L., Wong, R.N.S., and Tang, J. (1988) Synthesis, refolding, purification, and mutagenesis studies of recombinant porcine pepsinogen. *J. Cell Biol.* 107:1051.
4. Lin, X.L., Dashti, N., and Tang, J. (1989) Internal pH of the secretory granules in mouse pituitary AtT20 cells is above 5.0. The American Society for Cell Biology.
5. Lin, X.L., Fusek, M., and Tang, J. (1989) Purification and cloning of a new heat stable acid protease, thermopsin, from *Sulfolobus acidocaldarius*. Mid-America Molecular & Cellular Biology Colloquium, Shangri-La, Afton, OK.
6. Lin, X.L., Dashti, N., and Tang, J. (1990) Internal pH of the secretory granules in mouse pituitary AtT20 cells is above 5.0. American Society for Biochemistry and Molecular Biology.
7. Lin, X.L., Fusek, M., and Tang, J. (1990) Thermopsin, a thermostable acid protease from *Sulfolobus acidocaldarius*. Aspartic Proteinase Conference, Sonoma County, California.
8. Lin, X., and Tang, J. (1991) Expression and refolding of recombinant thermopsin. FASEB Meeting, Atlanta, Georgia, April, 1991.
9. Lin, X.L., Dashti, A., Schinazi, R.F., and Tang, J. (1991) A new strategy for gene therapy against AIDS: Intracellular diversion of gp160 of HIV to lysosomes for degradation. Technical Resources, Inc.
10. Lin, X.L., Dashti, A., Schinazi, R.F., and Tang, J. (1992) Intracellular diversion of envelope glycoprotein gp160 of human immunodeficiency virus to lysosomes for degradation. ASBMB.
11. Lin, X.L., Lin, Y.Z., Koelsch, G., Gustchina, A., Wlodawer, A., and Tang, J. (1992) Two-chain pepsinogen heterodimer and homodimer: Models for comparisons to the aspartic protease of human immunodeficiency virus. ASBMB.
12. Bian, J.H., Tang, J., and Lin, X.L. (1993) Heterologous expression and purification of HIV-1 gag protein p17. ASBMB/DBC-ACS.
13. Lin, X.L., and Tang, J. (1993) Alkaline inactivation of pepsin is due to denaturation of its N-Terminal lobe. ASBMB/DBC-ACS.

14. **Lin, X.** (1994) Structure and function of aspartic proteases. Lecturer and laboratory training, University of Coimbra, Portugal, May 23-June 6, 1994.
15. **Lin, X., and Tang, J.** (1994) A new retrovirus-based *in vivo* gene delivery system. Technological Advances for Gene Therapy, Washington, D.C., Nov. 29-30, 1994.
16. **Koelsch, G., Foundling, S., Tang, J., Loy, J., Monod, M., and Lin, X.** Recombinant secretory aspartic proteases from *Candida albicans*. ASBMB/DBC-ACS Joint Meeting, San Francisco, CA, May 21-25, 1995.
17. **Bian, J., Lin, X., and Tang, J.** (1995) Nuclear translocation of HIV-1 matrix protein P17: the use of *Aequorea victoria* green fluorescence protein in protein tagging and tracing. ASBMNB/DBC/ACS, 1995.
18. **Hong, L., Hartsuck, J.A., Lin, X., Treharne, A., Foundling, S., and Tang, J.** (1995) *In vitro* studies on the molecular basis of HIV protease mutants that resist inhibitors. Hovel HIV Therapies: From Discovery to Clinical Proof-of-Concept, Poster #32.
19. **Koelsch, G., Tang, J., Monod, M., Foundling, S., and Lin, X.** (1996) Primary substrate specificities of secreted aspartic proteases of *Candida albicans*. VIIth International Aspartic Proteinase Conference, Banff, Alberta, Canada, Oct. 22-27, 1996.
20. **Lin, X., and Tang, J.** (1998) *In vivo* gene delivering producer cells constructed from adenoviral and retroviral vectors. Keystone Molecular and Cellular Biology Symposia (Molecular and Cellular Biology of Gene Therapy Conference), Keystone, CO, Jan. 19-25, 1998.
21. **Lin, X.** "Studies on human memapsins". Sept. 11, 1999. In: *The 8th International Conference on Aspartic Proteinases*, Funchal, Madeira, Portugal, Sept. 7-12, 1999. Organizing Committee Chairman: Dr. Carlos Faro, University of Coimbra, Portugal.
22. **Lin, X.** November 12, 1999. "Identification of memapsin 2 as the -secretase that processes the amyloid precursor protein: implications in the treatment of Alzheimer's Disease". College of Life Science, Peking University, Peking, China.